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Glial cell line-derived neurotrophic factor (GDNF) is an extracellular
signaling protein that is produced by skeletal muscle and is important for the motor
neurons that control muscle movement. GDNF has been shown to keep neurons alive
under conditions that they would otherwise not persist. In skeletal muscle, GDNF
has been shown to be one of the most potent neurotrophic factors that influence motor
neuron survival. While the role of GDNF has been well studied during early
development, not much is known about what happens to GDNF expression in the
adult and with advanced aging. Previous results from our lab have demonstrated that
GDNF protein content in the adult can be significantly altered with exercise. It was
the purpose of these studies to determine the effects of aging and activity on GDNF
protein expression in rat skeletal muscle.
We found that GDNF expression was not significantly altered throughout the
majority of adulthood until it significantly increased at 19 and 23 months of age.
This time frame overlaps with onset of sarcopenia (age-related muscle loss and
weakness). We also found that changes in GDNF, both in early and in late-life

stages, appeared to be specific to skeletal muscle type. These results suggest that
changes in GDNF and/or its ability to signal to motor neurons may be involved in
age-related changes that occur in skeletal muscle.
Additionally we investigated how GDNF expression is altered with activity.
When we stimulated skeletal muscle to contract we observed significant changes in
GDNF protein content in skeletal muscle. Again we found that these responses were
specific to skeletal muscle type. Further investigation determined that the receptors
for the neurotransmitter, acetylcholine, appeared to be involved in the regulation of
GDNF protein expression with activity. These results provide a better understanding
of how GDNF protein expression is regulated in skeletal muscle.

UMI Number: 3278717

UMI Microform 3278717
Copyright 2007 by ProQuest Information and Learning Company.
All rights reserved. This microform edition is protected against
unauthorized copying under Title 17, United States Code.

ProQuest Information and Learning Company
300 North Zeeb Road
P.O. Box 1346
Ann Arbor, MI 48106-1346

Copyright by
Nathan Peplinski
2007

ACKNOWLEDGMENTS
I would like to thank my advisor Dr. John Spitsbergen for guiding me through
this entire process and helping me to grow both personally and professionally. I
would like to thank my family for all of their love and support over the years. Last,
and most certainly not least, I would like to thank my wife, Stephany, who has been
supportive throughout every step of this journey. I look forward to the adventures
that lie ahead and I am proud of the path left behind.
Nathan Peplinski

ii

TABLE OF CONTENTS
ACKNOWLEDGMENTS ......................................................................................

ii

LIST OF FIGURES ................................................................................................

vi

CHAPTER
I.

II.

III.

IV.

INTRODUCTION ................................................................................

1

Neurotrophic Factors...........................................................................

1

GDNF ..................................................................................................

4

Skeletal Muscle ...................................................................................

7

GDNF in Skeletal Muscle ...................................................................

9

EXPERIMENTAL DESIGN ................................................................

13

Specific Aims ......................................................................................

13

Preliminary Data and Troubleshooting ...............................................

16

HISTOLOGY ......................................................................................

26

Introduction .........................................................................................

26

Materials and Methods ........................................................................

28

Results and Discussion........................................................................

31

Summary..............................................................................................

50

GDNF WITH AGING ..........................................................................

51

Introduction .........................................................................................

51

Materials and Methods ........................................................................

53

iii

Table of Contents—continued
IV.

V.

VI.

GDNF WITH AGING ..........................................................................

51

Results .................................................................................................

55

Discussion ...........................................................................................

67

Summary..............................................................................................

74

GDNF WITH VOLUNTARY RUNNING ..........................................

75

Introduction .........................................................................................

75

Materials and Methods ........................................................................

77

Results .................................................................................................

78

Discussion ...........................................................................................

81

Summary..............................................................................................

84

BATH STUDIES ..................................................................................

85

Introduction .........................................................................................

85

Materials and Methods ........................................................................

87

Results .................................................................................................

91

Discussion ........................................................................................... 100
Summary.............................................................................................. 107
VII.

DISCUSSION AND CONCLUSIONS ................................................ 108
Disclaimer and Disclosure................................................................... 108
Histology ............................................................................................. 108
Aging ................................................................................................... 112
Voluntary Running .............................................................................. 115
Bath Studies......................................................................................... 118
iv

Table of Contents—continued
Conclusions ......................................................................................... 120
BIBLIOGRAPHY................................................................................................... 121

v

LIST OF FIGURES
1. There is no significant effect of ‘handedness on GDNF protein
expression in hind limb skeletal muscles of 7 month old rats .......................

20

2. There is a significant effect of ‘sided-ness’ on GDNF protein
expression in FDS but not EDL of 7 month old rats .....................................

22

3. There are no significant differences in GDNF protein content between
regions of the FDS in four month old F344 rats ............................................

25

4. GDNF is expressed in the region of the NMJ in rat EDL..............................

32

5. GDNF is expressed in the region of the NMJ in rat EDL..............................

33

6. GDNF is expressed at the NMJ in rat EHL ...................................................

36

7. GDNF is expressed at the NMJ in rat EDL ...................................................

37

8. GDNF is expressed at the NMJ in rat SOL ...................................................

38

9. GDNF is expressed at the NMJ in both EDL and SOL .................................

39

10. Slow myosin staining for three hind limb skeletal muscles...........................

43

11. GDNF is expressed at neuromuscular junctional regions that are not
associated with fast-intermediate myosin ......................................................

44

12. GDNF is expressed at the neuromuscular junctions associated with
slow myosin ...................................................................................................

46

13. GDNF is expressed in intrafusal muscle fibers of rat skeletal muscle ..........

49

14. GDNF protein content of the FDS is highest at 19 months of age ................

56

15.

GDNF protein content of the EDL is highest at 19 months of age................

57

16.

GDNF protein content of the VI is highest at 19 months of age ...................

58

17. GDNF protein content of the EDL remains constant with age......................

60

18. GDNF protein content of the FDS fluctuates with age..................................

61

vi

List of Figures—continued
19. GDNF protein content of the SOL fluctuates with age .................................

62

20. The SOL contains significantly more GDNF protein than the EDL and
FDS at 1 month of age ...................................................................................

64

21.

The FDS contains significantly less GDNF protein than the SOL and
EDL at 10 months of age ...............................................................................

65

The SOL contains significantly more GDNF protein than the EDL and
FDS at 23 months of age................................................................................

66

23. Effects of voluntary running on GDNF protein content in rat EDL..............

79

24. Effects of voluntary running on GDNF protein content in rat FDS ..............

80

25. Effects of field stimulation on GDNF protein content of hindlimb
skeletal muscles .............................................................................................

92

26. Effects of field stimulation on GDNF protein content of hind limb
skeletal muscles after treatment with α-bungarotoxin ...................................

93

27. Effects of α-bungarotoxin on GDNF protein content of hindlimb
skeletal muscles .............................................................................................

94

22.

28.

Effects of stretch on GDNF protein content of hindlimb skeletal
muscles...........................................................................................................

96

29. Effects of stretch with α-bungarotoxin on GDNF protein content of
hindlimb skeletal muscles ..............................................................................

97

30. Effects of carbachol on GDNF protein content of hindlimb skeletal
muscles...........................................................................................................

99

vii

CHAPTER I
INTRODUCTION
Neurotrophic Factors
Neurotrophic factors are a class of proteins that support the development,
maintenance and survival of neurons. They are produced by various cell types which
can either be the targets of the neurons themselves or supportive, ancillary cells.
They are released and diffuse across extracellular regions to act as extracellular
signaling proteins. Neurotrophic factors have many roles within an organism.
The word “neurotrophic” literally means nerve-nourishing. These classes of
molecules demonstrate the ability to increase the survival of neurons under various
conditions that they may not otherwise persist (Lin et al. 1993; Oppenheim et al.
1995; Arce et al. 1998).

Early observations of this physiological phenomenon

brought about an exciting new class of proteins to investigate with unknown
possibilities.
Neurotrophic factors are part of a larger family of growth factors present
throughout the body. Growth factors are important for improving cell proliferation
and growth. They guide development of tissues and act to help maintain homeostasis.
Two main families of growth factor proteins have been identified as neurotrophic.
These include the Neurotrophin family and the Glial cell line-derived neurotrophic
factor (GDNF) Family.

1

The Neurotrophin family of neurotrophic factors include; nerve growth factor
(NGF), brain-derived neurotrophic factor (BDNF), neurotrophin 3 (NT-3), and
neurotrophin 4/5 (NT-4/5). These ligands share a binding affinity for a family of
related tyrosine kinase receptors (Trk) that promote neuron survival as well as an
affinity toward a separate, pro-apoptotic p75NR receptor. All of the neurotrophin
family ligands demonstrate the ability to bind to the p75NR receptor (Chao 1994),
while the affinity for the Trk family of receptors is ligand/receptor specific; NGF
binds to TrkA, BDNF and NT-4/5 bind to TrkB, and NT-3 binds to TrkC (Barbacid
1994; Bothwell 1995; Kaplan and Miller 2000). While both the Neurotrophin family
and the GDNF families of neurotrophic factors promote the survival of neurons they
are two distinct classes of molecules.
The GDNF family of neurotrophic factors consists of GDNF, neurturin
(NTRN), artemin (ARTN), and persephin (PSPN). Like the Neurotrophin family,
they too activate a tyrosine kinase receptor called c-Ret, however signaling through cRet is mediated by a specific co-receptor for each molecule. These co-receptors are
glycosyl phosphatidylinositol (GPI)-linked receptors that preferentially bind to the
GDNF receptors in the following manner; GDNF binds to GFRα1, NTRN binds to
GFRα2, ARTN binds to GFRα3, and PSPN binds to GFRα4 (Airaksinen et al. 1999).
However a varying degree of ligand/receptor crosstalk within the GDNF family does
exist.
While the aforementioned ligand/receptor pairing is the preferred interaction
in vivo, some ligands demonstrate weak affinities towards other receptors in the
family. Both NTRN and ARTN can associate with GFRα1. GDNF may have the
2

ability to signal through GFRα2 and GFRα3 however PSPN has been shown to only
signal through GFRα4 (Lindahl et al. 2001; Airaksinen and Saarma 2002).
Furthermore GDNF has been shown to signal through GFRα1 independent of c-Ret
(Poteryaev et al. 1999; Trupp et al. 1999) while NTRN is unable to signal in the
absence of c-Ret (Pezeshki et al. 2001). While signaling in the GDNF family of
neurotrophic factors may be complicated this overlap in cellular signaling may be a
method of conservation.
The GDNF family of neurotrophic factors has been shown to be important for
normal physiological development.

Mice that lack both gene copies for either

GDNF, GFRα1, or c-Ret all die shortly after birth due to multiple neurological
failures during development including improper renal formation (Sanchez et al. 1996;
Airaksinen and Saarma 2002). Neurturin or GFRα2 knock-out mice grow poorly after
weaning and demonstrate a loss of multiple types of neuronal populations within an
organism (Heathcote and Sargent 1987; Enomoto et al. 2000; Nanobashvili et al.
2000). This is in contrast to both the ARTN or GFRα3 and the GFRα4 knock-out
animals that demonstrate only minor phenotypic changes and the selective loss of
only a few neuronal subtypes solely in the peripheral nervous system (Nishino et al.
1999; Hiltunen et al. 2001).
Of the GDNF family of neurotrophic factors only GDNF and NTRN were
discovered for their functional activity while both ARTN and PSPN were later
discovered by similarities in their gene sequence to the other two family members
(Baloh et al. 2000). While both GDNF and NTRN molecules are important for
normal neurological development and function, the consequences of GDNF knockout
3

in relative comparison to NTRN knockout has a distinctly more severe phenotypic
effect. Due to GDNF’s important biological activity and its role in both the normal
neuronal development and function it is an excellent candidate for functional studies.
GDNF
Glial cell line-derived neurotrophic factor (GDNF) was first discovered in
1993 and found to enhance the survival of midbrain dopaminergic neurons (Lin et al.
1993). It was further characterized as belonging to the TGF-β superfamily of growth
factors. It is an extracellular signaling protein that forms a homodimer to become
biologically active. Each mature GDNF protein monomer is comprised of 134 amino
acids and is approximately 15 kDa before it becomes glycosylated. The full mRNA
sequence is 633 base pairs (bp) of nucleotides which encodes for 211 amino acids. It
is believed that alternative spicing of the mRNA is responsible for producing a
second mRNA of 555-558 bps (Springer et al. 1995; Trupp et al. 1995; Suzuki et al.
1998).
This shorter version of GDNF cDNA is a result of a 78 bp deletion in the
prepro region of the coding sequence (Trupp et al. 1995). The resultant 26 amino
acid deletion also results in a change of Gly25 into an Ala. However no differences
in mobility were observed between the mature GDNF proteins formed from either of
the cDNA sequences (Trupp et al. 1995). It is still unclear if the alternative forms of
GDNF have distinctly separate functions.
Springer et. al. (1995) speculates that this may be a method of autoregulation, as proteins produced from the smaller splice variant of acidic fibroblast
4

growth factor act as an antagonist to the larger form of this growth factor (Yu et al.
1992). In the Neurotrophin family both NGF and BDNF have biologically active
pro- forms of their respective neurotrophic factors. For NGF it is the pro-NGF form
that binds with high affinity to the pro-apoptotic p75 receptor (Hempstead 2006).
This is in direct contrast to the pro-survival pathways activated by NGF signaling
through the TrkA receptor. For BDNF it is even more complex as 7 different splice
variants of mRNA are present, from which 4 different pro-BDNF proteins are
derived. Pro-BDNF 1-3 isoforms can all be processed to become the mature BDNF
with similar characteristics and are ~14 kDa monomers, while pro-BDNF 4 has a
sequence deletion and its protein is expressed as a 10 kDa monomer (Diamond et al.
2005).
The exact sequences of the events involved in GDNF protein processing are
not well characterized. It is known that the mature GDNF protein monomer is
smaller than the amino acid sequence after translation suggesting a protease cleavage
of the full protein. The enzymes involved and the exact locations of these events are
not known at this time. The resulting mature GDNF protein monomer becomes
glycosylated and is disulfide bonded to another monomer to become a homodimer
(Lin et al. 1993).

This mature homodimer is released by target tissues and is

considered the biologically active form which can initiate signaling with the
GFRα1/c-Ret complex.
Once GDNF binds to GFRα1/c-Ret complex the internal tyrosine residues on
c-Ret become phosphorylated.

Activation of c-Ret initiates several signaling

cascades that regulate cell survival, proliferation, neurite outgrowth, differentiation,
5

and synaptic plasticity (Sariola and Saarma 2003). c-Ret also forms from a splice
variant and the receptor proteins can be displayed in either a long or a short isoform.
While most of the physiological activity associated with c-Ret knockout studies can
be rescued by solely expressing the short form (de Graaff et al. 2001), the short-form
only has three tyrosine residues that become phosphorylated while the long-form has
an additional tyrosine (Tyr1096) that is phosphorylated. These two isoforms of c-Ret
activate different signaling complexes (Tsui-Pierchala et al. 2002) and each complex
is dependent upon the association of c-Ret to lipid rafts in the cell membrane. GDNF
has also been shown to initiate cell signaling independent of c-Ret.
Recently it has been demonstrated that GDNF can signal in a c-Ret
independent manner by binding to GFRα1 and associating with a yet unknown
transmembrane protein. Signaling in the absence of c-Ret initiates Src-family kinase
phosphorylation and activation of ERK/MAP kinase, PLC-γ, Fos, and the
transcription factor CREB protein (Trupp et al. 1999). GDNF signaling requires
heparin sulfate glycosaminoglycans (Barnett et al. 2002) as well as GFRα1. It is
suggested that this unknown transmembrane protein may use heparin sulfate
proteoglycans to associate with GFRα1 and initiate this c-Ret independent signaling
cascade (Sariola and Saarma 2003).
By studying the signaling cascades activated by GDNF we are provided with
specific molecular insight as to how GDNF affects the neuron and how it generates
its neurotrophic activity. However it still remains that in order for GDNF to initiate
these cellular pathways it must first be produced by a source and released before it
can have an impact on the neuron. There are many sources of GDNF throughout the
6

body (Suter-Crazzolara and Unsicker 1994; Trupp et al. 1995; Golden et al. 1999).
These tissues may work individually or collectively to provide trophic support to
nearby neurons. One such source is skeletal muscle.
Skeletal Muscle
The nerves that communicate with skeletal muscle cells rely on GDNF and
other neurotrophic factors for survival. Skeletal muscle is a diversely innervated
tissue. It receives nerve input from a specific group of neurons called motor neurons
that originate from the spinal cord. These neurons are responsible for stimulating the
skeletal muscle to contract and provide locomotion.

Skeletal muscle is also

innervated by sensory neurons that communicate with the CNS about muscle fiber
length to help coordinate locomotion and proprioception. Both the motor neurons
and sensory neurons are trophically supported by GDNF. However, the association
with sensory neurons decreases shortly after development and its effects on sensory
neurons are minimal when compared to other neurotrophic factors (Buj-Bello et al.
1995; Trupp et al. 1995).
Skeletal muscle fibers themselves are a diverse population of adaptable cells
with various phenotypes. There are two main categories of skeletal muscle fibers;
intrafusal and extrafusal muscle fibers. Each skeletal muscle fiber type has a specific
role within the tissue. Intrafusal muscle fibers, often called muscle spindle fibers,
have contractile regions on the distal ends of the cell and a non-contractile region in
the center. In this non-contractile region these muscle fibers have adapted sensory
apparatus that detect the tension and position relationship of the muscle. Sensory
7

neurons can then relay sensory information about muscle position in both a reflex arc
and to the motor cortex of the brain for advanced coordination of muscle movement.
Along with the sensory innervation of intrafusal muscle fibers they are also
contacted by motor neurons.

These neurons are responsible for controlling the

contractile portions of the intrafusal muscle fibers to “reset” the muscle fiber so that
tension remains constant as skeletal muscle position changes with coordinated
movement. It has been recently demonstrated that GDNF is highly expressed in these
intrafusal muscle fibers and that its role in these fibers may be to trophically support
the motor neuron innervation of these fibers (Whitehead et al. 2005).
Extrafusal muscle fibers are the muscle fibers responsible for generating the
force associated with muscle contraction.

These make up the majority of the

composition of the skeletal muscle and can further be divided into two basic
phenotypes. These two extrafusal skeletal muscle fiber phenotypes are classified by
their metabolic function associated with myosin ATPase activity. These skeletal
muscle fibers can be classified as either slow-(type I or slow oxidative) or fast-twitch
muscle fibers.
Of the fast-twitch muscle fibers there exist three different subtypes. These
subtypes include; type IIA (fast-oxidative, fast fatigue-resistant), type IID/X (fast
intermediate fatigability), and IIB (fast glycolytic, fast fatigable)(Schiaffino et al.
1989; Staron et al. 1999). Some skeletal muscles do contain muscle fibers that
appear as combinations of these four phenotypes however their presence is usually
minimal and may or may not be present in various skeletal muscles. Skeletal muscle
fiber type may be related to GDNF protein expression.
8

Nagano et. al. (2003)

determined the pattern of GDNF expression of both mRNA and protein content of
developing rat skeletal muscles differed when comparing the soleus (a primarily
slow-twitch skeletal muscle) to the gastrocnemius (a primarily fast-twitch skeletal
muscle). Fast- and slow-twitch muscle fibers are contacted by motor neurons that
also display fast and slow signaling dynamics (Edstrom and Kugelberg 1968; Burke
et al. 1973). It may be inferred then that if GDNF is selectively expressed in a
particular skeletal muscle fiber subtype, then it may be important for supporting a
selective subtype of motor neuron as well.
GDNF in Skeletal Muscle
The role of GDNF in skeletal muscle has been primarily associated with the
support and maintenance of motor neurons. It has been demonstrated that GDNF is
one of the most potent neurotrophic factors for motor neurons (Henderson et al. 1994;
Oppenheim et al. 1995; Trupp et al. 1995; Yan et al. 1995; Nguyen et al. 1998).
GDNF has been shown to rescue motor neurons from cell death due to both naturally
occurring apoptosis in development (Henderson et al. 1994; Oppenheim et al. 1995;
Yan et al. 1995; Nguyen et al. 1998; Oppenheim et al. 2000; Zwick et al. 2001) as
well as recovery from motor neuron injury (Lie and Weis 1998; Chen et al. 2001;
Boyd and Gordon 2003). GDNF has also been shown to decrease the motor neuron
damage associated with degenerative neuropathies (Sagot et al. 1996; Suzuki et al.
1998; Corse et al. 1999; Yamamoto et al. 1999; Wang et al. 2002). While its
importance for motor neuron survival has been well established some have noticed
that GDNF appears to only effect a subpopulation of motor neurons.
9

Functional

studies

of

GDNF-deficient

and

GFRα1-deficient

mice

demonstrated that only 22-35% of spinal motor neurons were lost at birth (Moore et
al. 1996; Sanchez et al. 1996; Cacalano et al. 1998; Oppenheim et al. 2000). This
suggests that there may be GDNF-dependent and GDNF-independent subpopulations
of motor neurons.

Furthermore histochemical analyses of sciatic nerve bundles

demonstrate that GFRα1 is expressed preferentially in 25% of the motor neurons
(Bergman et al. 1999). And GDNF protein labeling of the axons in intramuscular
nerve bundles demonstrated increased GDNF signal from the large diameter axons in
human skeletal muscle (Suzuki et al. 1998). However, without a specific marker for
motor neuron subtype, identification of the GDNF-dependent subtype has not yet
been determined.
A recent finding in our lab demonstrated that GDNF protein expression in
skeletal muscle is regulated in an activity-dependent manner (Wehrwein et al. 2002).
Others have since determined that exercise after nerve injury increases the
neurotrophic effects of GDNF in rat soleus (Dupont-Versteegden et al. 2004). We
demonstrated that increased exercise with walk-training causes a significant increase
in GDNF protein content, while skeletal muscle inactivity associated with hind limb
suspension caused a significant decrease in the unloaded skeletal muscles.

In

contrast, the forelimb skeletal muscles in the hind limb unloaded experiments
increased their GDNF protein content. An interesting comparison, however, was that
GDNF protein content was significantly higher in the primarily slow-twitch skeletal
muscle

(soleus)

compared

to

the

primarily

fast-twitch

skeletal

muscle

(gastrocnemius). These differences in skeletal muscle expression with activity may
10

be associated with the fiber-type composition. Therefore, current studies were
designed to address the specific responses of skeletal muscles with various fiber-type
compositions in response to exercise and activity. While little is still known about
the regulation of GDNF expression in skeletal muscle with exercise and activity, even
less is known about GDNF expression with advanced aging.
With skeletal muscle aging there is a significant loss of skeletal muscle mass.
This process, called sarcopenia, is characterized by a loss of approximately one-third
of normal adult muscle mass and occurs in humans from age 20-80 (Rosenberg
1997). During the process of sarcopenia, skeletal muscles selectively lose fast-twitch
muscle fibers in a process that is still unclear. Both fast-twitch muscle fibers and the
fast-firing motor neurons are significantly decreased with age (Brown 1972; Brown et
al. 1988; Kanda and Hashizume 1998; Roubenoff and Hughes 2000). However,
slow-twitch muscle fibers appear to be less affected and often sprout axonal processes
to take over the vacated NMJs left behind on the denervated fast-twitch muscle fibers
(Rosenberg 1997; Roubenoff and Hughes 2000). The result is an age-dependent shift
in fiber-type composition from a fast- to a slow-twitch phenotype and an overall loss
of skeletal muscle mass.

As expected, age-related changes associated with

sarcopenia occur more in skeletal muscles that have a primarily fast-twitch muscle
fiber-type composition and less in skeletal muscles that have a primarily slow-twitch
muscle fiber-type composition.
One possible cause for the loss of motor neurons and the fiber-type switching
that occurs with advanced aging could be due to alterations in neurotrophic factor
expression and/or signaling. Since GDNF has been shown to be one of the most
11

potent neurotrophic factors for motor neurons, then alterations in GDNF content
and/or signaling may be involved in age-related motor neuron loss. Bergman et. al.
(1999) determined that both GFRα1 and c-Ret mRNA and protein are up-regulated on
spinal motor neurons of aged rats. However, the effect of aging on skeletal muscle
production of GDNF protein has not yet been determined. It is therefore important
and necessary to determine if age-related changes in GDNF protein content occur in
skeletal muscle in order to better understand the possible role of GDNF in the process
of sarcopenia.

12

CHAPTER II
EXPERIMENTAL DESIGN
Specific Aims
The broad objective of our lab is to gain a better understanding of the bidirectional communication that occurs between neurons and the target tissues that
they innervate. We are focused primarily on determining the role that neurotrophic
factors have in this communication as well as investigating signals that alter their
expression. We are specifically interested in the production of a type of neurotrophic
factor called glial cell line-derived neurotrophic factor (GDNF). It is the aim of this
research to determine where GDNF protein is expressed in skeletal muscle and to
determine what can alter expression of GDNF protein in skeletal muscle. To achieve
these aims we will test the following hypotheses;

1.

GDNF protein is concentrated at the area of the neuromuscular
junction (NMJ).

To determine where GDNF is located in skeletal

muscle:

a.

We will use antibody labeling against GDNF protein and view
the NMJ region in both longitudinal and cross-sectional
analyses.
13

b.

We will do a sectional analysis of skeletal muscle and measure
the GDNF protein content in each section as it relates to
endplate density.

2.

The process of aging alters GDNF protein expression in skeletal
muscle. To determine how aging affects GDNF protein content:

a.

We will measure GDNF protein content of various hind limb
skeletal muscles in animals at early, mid, and late life stages of
aging.

3. Voluntary exercise alters GDNF protein expression in skeletal muscle.
To determine how voluntary exercise affects GDNF protein content:

a.

We will train animals to exercise voluntarily and measure the
effect of a long bout of exercise on GDNF protein content of
skeletal muscles.

b.

We will train animals to exercise voluntarily and measure the
effect of an acute bout of exercise after a long bout of exercise
on GDNF protein content of skeletal muscles.

4. Skeletal muscle stretch alters GDNF protein expression. To determine
how physical stretch affects GDNF protein content:
14

a.

We will subject skeletal muscle to repetitive stretching and
measure the amount of GDNF protein expressed.

b.

We will block AChRs using α-bungarotoxin, stretch the
muscle, and measure the amount of GDNF protein expressed.

5. Acetylcholine receptor activity alters GDNF protein expression. To
determine how acetylcholine receptor activity affects GDNF protein
content:

a.

We will block AChRs using α-bungarotoxin and measure the
amount of GDNF protein expressed. (no ACh activity, no
electrical stimulation)

b.

We will block AChRs using α-bungarotoxin, stimulate the
muscle via electric field and measure the amount of GDNF
protein produced. (no ACh activity, but electrical stimulation)

c.

We will directly activate AChRs using carbachol and measure
the amount of GDNF protein expressed.

15

Testing these specific hypotheses will further our understanding of
neurotrophic factor regulation in skeletal muscle. The results of these experiments
may elucidate mechanisms that are responsible for exercise related changes that occur
in skeletal muscle as well as provide insight as to the possible role of GDNF in agerelated changes in skeletal muscle.

Preliminary Data and Troubleshooting
The methods of all of the following experiments are explained in detail in
their corresponding chapters. It is the purpose of this section to explain the trials and
tribulations that led up to their current form and give insight as to how these methods
came about.

Skeletal Muscle Selection
There appears to be an underlying theme suggested by results from ours and
others’ previous studies (Wehrwein et al. 2002; Nagano and Suzuki 2003). Skeletal
muscles respond to exercise with a change in GDNF protein content and it is possible
that these responses may be tissue dependent. It is because of this possibility that we
decided to compare the results for all of our studies using a variety of hind limb
skeletal muscles. We chose both the soleus (SOL) and extensor digitorum longus
(EDL) muscles because of their vast differences in muscle fiber-type composition,
physiological function, neuronal input, and metabolic activity (Alnaqeeb and
Goldspink 1987; Reid et al. 2003; Patterson et al. 2006). With respect to skeletal
muscle fiber-type composition, these two tissues represent an almost completely
16

opposite expression pattern. The SOL is composed primarily of slow-twitch muscle
fibers while the EDL is composed primarily of fast-twitch muscle fibers.

It is

because of these differences that these two tissues have been compared classically
throughout skeletal muscle activity studies (Alnaqeeb and Goldspink 1987; Windisch
et al. 1998; Gissel and Clausen 1999; Copray et al. 2000; Plant et al. 2001; Reid et al.
2003).
While we hoped to compare and contrast the responses of these two tissues
with respect to activity and aging, an unknown technical problem did not come to
light until late into our investigation. We had been mistakenly removing the flexor
digitorum superficialis (FDS) skeletal muscle instead of the SOL. While results from
the SOL have been well documented in the literature, the FDS has not been
extensively studied. In the rat, the FDS is larger than both the SOL and EDL in size
and works in opposition to the EDL. In the human, the muscle is deep and not
superficial and is therefore named flexor digitorum longus (FDL). The FDL has a
much longer distal tendon than the FDS in the rat and is relatively smaller in size to
human EDL and SOL. These differences between rat FDS and human FDL make it
increasingly difficult to draw direct comparisons between the two different species.
The relative composition of rat FDS was determined to contain 8% slowtwitch muscle fiber counts (Ariano et al. 1973) but published reports of muscle typefiber composition from this paper have differed slightly compared to more recent
values published by other researchers (Armstrong and Phelps 1984; Alnaqeeb and
Goldspink 1987; Chamberlain and Lewis 1989).

We have also provided visual

evidence of its relative slow fiber-type composition compared to both the SOL and
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the EDL (Figure 10). We concur that the FDS is similar in composition to the EDL
with the majority of its muscle fibers being fast-twitch but it does appear to have
slightly higher slow-twitch muscle fiber content than EDL.
It is because of this misidentification that the majority of the bath studies
include results from all three muscles. It is also one of the main reasons why there
are two separate aging studies; the first did not include the real SOL and only had
results for the FDS and EDL.

The voluntary running study was also affected.

However, results were reported for the FDS and EDL and do not include data from
the SOL.
In the first of the two aging studies another muscle called the vastus
intermedius (VI) was used for only a few of the time points investigated (7 month, 9
month, and 19 month). This tissue was selected because the literature suggested that
it may represent a hind limb skeletal muscle with a relatively mixed distribution of
fast- to slow-twitch muscle fiber composition (Ariano et al. 1973).

However

technical difficulties in the reliable removal of this tissue cause complications. The
VI inserts onto the medial portion of the rat femur in a fan-like array and removal of
this insertion often resulted in a varying degree of muscle fiber damage.
Furthermore, the VI had a poorly defined border with its neighboring quadriceps
muscles the vastus medialis and the vastus lateralis. Removal of the VI at times also
included partial removal of either of these two tissues and was inconsistent
throughout. It is because of these technical difficulties that the VI was no longer used
for the other time points investigated or for any of our other studies.
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Another tissue selected for study was the extensor hallucis longus (EHL). It
has identical function to the EDL (to extend the digits of the foot), but the EDL
extends phalanges II-V while the EHL extends the hallux bone (a.k.a. the big toe).
This tissue was chosen because its function is similar to that of the EDL but with its
relatively much smaller size, it is more useful for histological analyses. The EHL
was used in whole-mount, free-floating, preparations for longitudinal visualization of
skeletal muscle histochemistry.

Handedness
One observation from previous studies in our lab was that even in a control
group of animals, GDNF protein content of skeletal muscle appeared to be variable at
times. After review of the previous methods used in the lab, whereby the right side of
the animal’s paired skeletal muscles were used for GDNF protein quantification using
and enzyme linked immunosorbant assay (ELISA) and the left side used for
histology, we decided to examine the possibility of “handedness” in GDNF protein
expression.
In a preliminary study of control animals we examined the GDNF protein
content of the flexor digitorum superficialis (FDS) and extensor digitorum longus
(EDL) in seven month old Sprague Dawley rats.

We found that there was no

significant difference between the left versus the right side of these paired hind limb
skeletal muscles (Figure 1).

19

There is no significant effect of 'handedness' on
GDNF protein expression in hind limb skeletal
muscles of 7 month old rats.
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Figure 1. There is no significant effect of ‘handedness on GDNF protein expression
in hind limb skeletal muscles of 7 month old rats. Glial cell line-derived neurotrophic
factor protein content was measured in the flexor digitorum superficialis (FDS) and
extensor digitorum longus (EDL) muscles of seven month old Sprague-Dawley rats.
Paired left and right hind limb muscles were removed, frozen on dry ice, and
processed for determination of GDNF protein content using and enzyme-linked
immunosorbant assay. There was no significant difference in the left versus the right
skeletal muscle GDNF protein content for either the FDS or the EDL (n = 6).
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When comparing the left versus the right side for these tissues there was no
statistically significant difference in GDNF protein content. It might have been that if
GDNF protein content was affected by an inherent dominate “handedness,” then our
results could have been skewed by one or two of our animals being left-side dominate
while the rest of the animals may have been right-side dominate, or vice versa.
Without the ability to initially determine an inherent preference, we could not
correlate any of these possibilities with our results. We did notice a trend in the
values from each animal.
It appeared as though for each animal, while there was no distinct difference
from left versus right, there was a difference in expression in one side versus the
opposing side. If we ignored the left versus right classification and instead used the
null hypothesis that one side has greater GDNF protein content than the other, and
sorted our data so that within each animal we compared the muscle with the higher
GDNF protein content to the muscle with the lower GDNF protein content then our
results were significantly different for the FDS but not the EDL (Figure 2). It is
because of this that we were faced with a dilemma.
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There is a significant effect of 'sided-ness' on GDNF
protein expression in FDS but not EDL of 7 month old
rats.
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Figure 2. There is a significant effect of ‘sided-ness’ on GDNF protein expression in
FDS but not EDL of 7 month old rats. Glial cell line-derived neurotrophic factor
protein content was measured in the flexor digitorum superficialis (FDS) and
extensor digitorum longus (EDL) muscles of seven month old Sprague-Dawley rats.
Paired left and right hind limb muscles were removed, frozen on dry ice, and
processed for determination of GDNF protein content using and enzyme-linked
immunosorbant assay. GDNF protein content of each tissue was determined for each
animal and values were placed categorically into a group with the higher of the paired
values belonging to the highest group, and the lower of the paired values belonging to
the lowest group (n = 6). In this analysis, GDNF protein content was significantly
higher in the ‘highest’ group in the FDS but not significantly higher in the EDL.
These results suggest that for the FDS, within an animal, one side contains
significantly more GDNF protein content than its contralateral pair. (* = p ≤ 0.05)
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Without the advance knowledge of knowing which side may have started with
more GDNF before experimentation, manipulations like bath experiments could have
been greatly affected. In tissue bath experiments, both sides were used and compared
to one another. It would have been difficult to infer physiological changes from
control if one group had a significantly different basal level of GDNF protein content.
It is because of this possibility that we chose to randomly sort left- and right-sided
muscles into our control and experimental groups for all of the following bath
experiments. This random assortment may have increased the variability of the
absolute values of GDNF in the tissue, but since both the experimental and the
control groups are treated in this manner, then any differences between the groups
should have been due to the manipulation of the bath experiment itself and not to
inherent differences in baseline levels of GDNF protein content.

Skeletal Muscle Sectional Analysis
One of the objectives of these studies was to determine where in the tissue
GDNF protein is located. We proposed two methods to determine if GDNF protein
expression is increased in the region of the neuromuscular junction. The first method
was to use immunohistochemistry and the results of which are explained in the
following chapter. The second method proposed was to perform a sectional analysis
of skeletal muscle and determine GDNF protein content as it relates to endplate
density (Specific Aims 1b). This is based upon the assumption that most of the
innervation of skeletal muscle occurs in the belly of the tissue. We decided to dissect
the muscle into three equal pieces that represent the proximal, middle, and distal third
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of the skeletal muscle. According to the assumption the majority of the skeletal
muscle endplates should be in the middle section.

If GDNF protein content is

greatest near the region of the NMJ, then the middle section should have significantly
more GDNF protein content than the proximal or the distal segments.
Our results showed no significant difference between any of the three sections
when GDNF protein content is measured and compared (Figure 3). Upon further
investigation we checked our initial assumption that the majority of the endplates do
in fact occur in the middle section. We found that in the FDS, as well as in the SOL
and EDL, the orientation of the muscle fibers run diagonally along the muscle body.
The endplates also follow this diagonal orientation and thus, skeletal muscle
endplates were found dispersed evenly throughout the majority of the length of the
tissue.

Sectional analyses of GDNF protein content of skeletal muscles would

therefore not be a suitable method to determine if GDNF protein is preferentially
expressed near the region of the NMJ.
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T here are no significant differences in GDNF
protein content between regions of the FDS in four
month old F344 rats.
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Figure 3. There are no significant differences in GDNF protein content between
regions of the FDS in four month old F344 rats. In order to determine if there was a
regional expression of GDNF protein content in skeletal muscle, a sectional analysis
of the flexor digitorum superficialis (FDS) muscle was performed.
FDS were
removed from four month old male Fisher 344 rats (n = 4) and divided into three
equal sections representing the proximal, middle, and distal one-third of the muscle
respectively. Tissue sections were frozen on dry ice and processed for quantification
of GDNF protein content using an enzyme-linked immunosorbant assay. There was
no significant difference between any of the three segments with regards to GDNF
protein content.
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CHAPTER III
HISTOLOGY
Introduction
One of the specific aims of our research is to determine where within the
tissue glial cell line-derived neurotrophic factor (GDNF) protein is expressed.
Researchers have attempted labeling of endogenous GDNF protein in skeletal muscle
with varied success (Suzuki et al. 1998; Suzuki et al. 1998; Russell et al. 2000). Still
others have decided to avoid complications associated with labeling endogenous
GDNF protein and instead used genetically modified animals to express βgalactosidase-linked GDNF protein. These methods have been shown to be useful in
labeling the genetically modified GDNF protein; however these manipulations can
only be performed in mice and cannot be used in our system (Whitehead et al. 2005).
Suzuki et. al. (Suzuki et al. 1998) identified GDNF immunoreactivity to be
increased in the area of the NMJ for transversely-sectioned human skeletal muscle
biopsies. Russel et. al. (Russell et al. 2000) were unable to detect signs of increased
GDNF immunoreactivity at the neuromuscular junction (NMJ) of rat skeletal muscle.
This discrepancy in GDNF protein expression between these two species could be of
merit, or it might have been that differing methodology led to different results in
protein imaging.
We hoped to determine if GDNF protein is expressed at the NMJ in rat
skeletal muscle. Additionally, we hoped to include longitudinal views of the NMJ
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with the intent of improving GDNF protein imaging in skeletal muscle. Replication
of these previous methods in our tissues has historically been an arduous task with
inconsistent outcomes. We sought to enhance these imaging methods with the hopes
of increasing the reliability of the results. The following methods are the results of
many series of combined troubleshooting and tweaking that has accumulated over the
years to arrive in the current form.
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Materials and Methods

Tissue Preparation
Skeletal muscles were removed and placed in Zamboni’s fixative (Stefanini et
al. 1967) for 15 minutes. Tissues were then washed in phosphate buffered saline
solution ([PBS] 22.5 mM NaCl, 2.0 mM NaH2PO4, and 8.0 mM NaHPO4) three times
for 5 minutes each.

Samples to be processed as whole-mount, free-floating

preparations were then placed in PBS and stored at 4ºC.

Samples that were to be

used for transverse sectioning were placed in 2-methylbutane cooled on dry ice until
frozen. After freezing, tissues were placed in a sealed container and stored at -80ºC.

Primary Antibodies
Stock solutions were prepared and stored according to manufacturer’s
recommendations. The following primary antibodies were used at the following
concentrations; rabbit anti-GDNF (SC 328, Santa Cruz Biotechnologies) at 2.0
μg/mL, goat anti-GDNF (AF-212-NA, R & D Systems) at 5.0 μg/mL, mouse antislow myosin (M8421, Sigma-Aldrich) at 5.0 μg/mL, goat anti-GFRα1 (AF560, R &
D Systems) at 5.0 μg/mL, mouse anti-neurofilament H (MAB305, Chemicon) at 1.0
μg/mL, mouse anti-typeIIA myosin (805.503, Alexis Biochemicals), and mouse antiintrafusal fiber (S46-s, Developmental Studies Hybridoma Bank at the University of
Iowa) as undiluted cell culture supernatant.
All of the antibodies listed were prepared in blocking solution which
consisted of PBS containing 1% bovine serum albumin (1600-100, Fisher Scientific)
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and 0.3% Triton X-100 (T8787, Sigma-Aldrich). Also used were α-bungarotoxin488 (B13422, Molecular Probes), α-bungarotoxin-594 (B13423, Molecular Probes)
and α-bungarotoxin-Texas Red (00015, Biotium) all at 5.0 μg/mL.

Secondary Antibodies
All

secondary

antibodies

used

were

developed

to

recognize

the

Immunoglobulin G specific to the host organism that developed the corresponding
primary antibodies. Additionally they all were developed to be directly linked to
Alexa Fluor molecules for visualization. The following secondary antibodies were all
purchased from Molecular Probes and were used at 4.0 μg/mL; donkey anti-mouse647 (A31573), donkey anti-goat-568 (A11057), donkey anti-rabbit-488 (A21206),
goat anti-rabbit-488 (A11008), goat anti-rabbit 594 (A110120, goat anti-mouse-488
(A21121), and goat anti-mouse-594 (A110050.

Transverse Sections
Skeletal muscles were removed from storage and embedded in tissue
mounting medium (Tissue Tek O.C.T., Sakura).

Tissues were cut into 50 μm

transverse slices using a cryostat and thaw-mounted to glass slides (12-550-15, Fisher
Scientific). Slides were then washed 3 x 5 minutes in PBS and a 10% secondary
specific animal serum (either donkey or goat) was added to blocking serum and added
to the slide for 30 minutes at room temperature. Excess blocking solution was
drained from the slides and primary antibodies were added for 4 days at 4ºC. If αbungarotoxin was used, it was applied before the primary antibodies for 30 minutes at
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room temperature followed by washing with PBS 3 x 5 minutes. Following the
incubation in primary antibodies, slides were washed 3 x 5 minutes each with PBS
and the corresponding secondary was added for visualization. Slides were covered
with a 1:1 solution of PBS:glycerol and sealed with a coverslip. All slides were
viewed on a Zeiss laser scanning confocal microscope (LSM 510, Zeiss).

Free-floating Preparations
Skeletal muscles were removed from storage and washed 3 x 5 minutes with
PBS. For the EDL and SOL, these tissues were too large to process as whole-mounts
so the tissues were divided into 3 and 4 equal pieces respectively. For the extensor
hallucis longus (EHL), tissues were processed as whole-mounts. All procedures for
free-floating preparations mimic exactly the protocol above used for transverse
sections except that sufficient volumes were added to submerge the tissues and
perform each step in 1.5 mL Eppendorf tubes (T2422, Sigma-Aldrich). After the
final wash, tissues were transferred to a depression slide, covered with a 1:1 solution
of PBS:glycerol and sealed with a coverslip. All slides were viewed on a Zeiss laser
scanning confocal microscope (LSM 510, Zeiss).
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Results and Discussion

Neuromuscular Junction
According to the neurotrophic model, GDNF like other neurotrophic factors,
is produced by target tissues and released for uptake by motor neurons. If GDNF
protein can be detected in skeletal muscle, then the area of nerve-muscle contact may
be the most probable location for visualization of GDNF protein expression. We
determined that there is positive immunoreactivity in the region of the NMJ. We
were able to visualize positive staining for GDNF near the region of positive αbungarotoxin staining in transverse sections of rat EDL (Figures 4 and 5). We
noticed that GDNF immunoreactivity is increased near the region of the NMJ but we
were unable to determine if GDNF expression is within the skeletal muscle, on the
skeletal muscle membrane, or associated with the motor nerve terminal.

These

results suggest that rat GDNF protein is expressed at the NMJ similar to the pattern of
expression observed in human skeletal muscle (Suzuki et al. 1998; Suzuki et al. 1998;
Hase et al. 1999). The negative results observed by Russel et. al. (2000) might have
been due to complications with their histological methods.
Suzuki et. al. (1998) demonstrated positive GDNF immunoreactivity near the
NMJ in human skeletal muscle after applying the primary antibody to sectioned
skeletal muscle for 3 days at 4ºC. Russel et. al. (2000) applied primary antibody to
sectioned skeletal for 2 days at 4ºC and was unable to detect GDNF protein
immunoreactivity at the NMJ.
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GDNF is expressed in the region of the NMJ in rat EDL.

Figure 4. GDNF is expressed in the region of the NMJ in rat EDL. The extensor
digitorum longus (EDL) muscle was removed from four week old male SpragueDawley rats. The muscle was cut into 50 μm sections and fixed using Zamboni’s
fixative. Samples were treated with a blocking solution containing donkey serum for
30 minutes. Slides were drained and treated with α-bungarotoxin-488 for 30 minutes
for endplate visualization (green). Samples were washed and goat anti-GDNF
primary antibody was applied for 4 days. Slides were washed and donkey anti-goat568 secondary antibody was applied for 1 hour for GDNF visualization (red). Images
were captured using a Zeiss laser scanning confocal microscope. Also represented
above is an overlay of transmitted light to show skeletal muscle morphology. The
image above depicts increased GDNF immunoreactivity (red) in the region near the
neuromuscular junction (green).
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GDNF is expressed in the region of the NMJ in rat EDL.

Figure 5. GDNF is expressed in the region of the NMJ in rat EDL. The extensor
digitorum longus (EDL) muscle was removed from four week old male SpragueDawley rats. The muscle was cut into 3 equal pieces and fixed using 4%
paraformaldehyde for 15 minutes followed by ice cold methanol for 5 minutes.
Samples were treated with a blocking solution containing donkey serum for 30
minutes. Tissues were drained and treated with α-bungarotoxin-488 for 30 minutes
for endplate visualization (green, top left panel). Samples were washed and goat antiGDNF primary antibody was applied for 4 days. Tissues were washed and donkey
anti-goat-594 secondary antibody was applied for 1 hour for GDNF visualization
(red, top right panel). Images were captured using a Zeiss laser scanning confocal
microscope. The image above depicts increased GDNF immunoreactivity (red) in the
region near the neuromuscular junction (green, bottom left overlay).
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While the difference might have been minimal, our first attempts were
unsuccessful when primary antibody was applied for 1 day at 4ºC. It was not until
after we changed our protocol to include incubation of the primary antibody to be 4
days in duration at 4ºC were we able to successfully visualize GDNF protein at the
NMJ.

Furthermore, recent developments in our laboratory methods have

preliminarily demonstrated that the signal of GDNF protein immunoreactivity
increases and the amount of non-specific background staining decreases when we
incubate the primary antibody for 7 days and increase the duration of the secondary
antibody from 1 hour to 3 days at 4ºC (unpublished observations). The duration of
primary antibody exposure may only be partly responsible for the differences in the
imaging results between our studies and that of Russel et. al. (2000).
Publication materials from the GDNF primary antibody manufacturer (R&D
Systems) also suggest that the GDNF antigen may be a fixative sensitive antigen and
that prolonged exposure to 4% paraformaldehyde, might completely abolish GDNF
labeling. While it is unclear if this is a phenomenon specific to the antibody used, the
fixation protocols used for all 3 studies were different. Suzuki et. al. (1998) used 4%
paraformaldehyde for 15 minutes for fixation of skeletal muscle sections. Russel et.
al. (2000) also used 4% paraformaldehyde for fixation but exposed the tissue for 30
minutes. We decided to use Zamboni’s fixative (Stefanini et al. 1967) because of its
improved shelf-life and stability over that of paraformaldehyde. While it is still a
paraformaldehyde-based fixative, the approximate concentration of paraformaldehyde
is only 2% as opposed to 4%. We also exposed our tissues to fixative for 15 minutes
as opposed to 30 minutes.
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The differences in methods between our studies and the methods used by
Russel et. al. (2000) may account for the discrepancy in GDNF imaging at the NMJ.
These differences in methods, along with inherent differences involved in the use of
two different primary antibodies for GDNF, collectively or in part might have been
responsible for their lack of GDNF signal in rat skeletal muscle. We also hoped to
further characterize the phenotypic expression of GDNF immunoreactivity at the
NMJ by including longitudinal imaging of skeletal muscle.
Tissues were processed as free-floating preparations, as opposed to
transversely sectioned skeletal muscle, and displayed similar results. We were again
able to demonstrate increased GDNF immunoreactivity near the NMJ for a variety of
skeletal muscles using two different GDNF primary antibodies. The EHL (Figure 6),
the EDL (Figure 7), and the SOL (Figure 8) all displayed increased GDNF protein
immunoreactivity near the region of the NMJ. These images were all captured using
the same goat anti-GDNF antibody (AF-212-NA, R&D Systems). When these results
were compared to images attained using a different GDNF primary antibody (sc-382,
Santa Cruz Biotechnologies), GDNF protein was still expressed near the NMJ, but
the pattern of expression differed.
This second antibody (rabbit) we tested for labeling of GDNF protein was the
same antibody used by Russel et. al. (2000). We noticed a different pattern of
expression using the rabbit antibody (Figure 9).

35

GDNF is expressed at the NMJ in rat EHL.

A

B

Figure 6. GDNF is expressed at the NMJ in rat EHL. The extensor hallucis longus
(EHL) muscles were removed from four week old male Sprague-Dawley rats. The
muscles were fixed using Zamboni’s fixative for 15 minutes and processed as a freefloating preparation. Tissues were treated with a blocking solution containing donkey
serum for 30 minutes. Samples were drained and treated with α-bungarotoxin-594
(A, red) or α-bungarotoxin-488 (B, green) for 30 minutes for endplate visualization.
Samples were washed and goat anti-GDNF primary antibody was applied for four
days. Tissues were washed and donkey anti-goat-488 (A, green) or donkey anti-goat594 (B, red) secondary antibody was applied for one hour for GDNF visualization.
Images were captured using a Zeiss laser scanning confocal microscope. The images
above depict increased GDNF immunoreactivity (red) in the region near the
neuromuscular junction (green). Above left (A) represents endplates (red) and GDNF
(green) with a wide field of view. Above right (B) shows a magnified view of
endplates (green) and GDNF (red).
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GDNF is expressed at the NMJ in rat EDL.

A

B

Figure 7. GDNF is expressed at the NMJ in rat EDL. The extensor digitorum longus
(EDL) muscles were removed from four week old male Sprague-Dawley rats. Whole
EDL were too large to process in a free-floating preparation so tissues were divided
lengthwise into three equal pieces. The muscles were fixed using Zamboni’s fixative
for 15 minutes. Tissues were treated with a blocking solution containing donkey
serum for 30 minutes. Samples were drained and treated with α-bungarotoxin-594
(A, red) or α-bungarotoxin-488 (B, green) for 30 minutes for endplate visualization.
Samples were washed and mouse anti-neurofilament H (B only) and goat anti-GDNF
primary antibodies were applied for 4 days. Tissues were washed and donkey antigoat-488 (A, green) or donkey anti-goat-594 (B, red) secondary antibody was applied
for 1 hour for GDNF visualization along with donkey anti-mouse-647 (B, blue) for
neurofilament visualization. Images were captured using a Zeiss laser scanning
confocal microscope. The images above depict increased GDNF immunoreactivity in
the region near the neuromuscular junction. Above left (A) represents endplates (red)
and GDNF (green) with a wide field of view. Above right (B) shows a magnified
view of endplates (green), GDNF (red), and nerve fiber (blue).
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GDNF is expressed at the NMJ in rat SOL.

Figure 8. GDNF is expressed at the NMJ in rat SOL. The soleus (SOL) muscles
were removed from four week old male Sprague-Dawley rats. Whole SOL muscles
were too large to process in a free-floating preparation so tissues were divided
lengthwise into four equal pieces. The muscle pieces were fixed using Zamboni’s
fixative for 15 minutes. Tissues were treated with a blocking solution containing
donkey serum for 30 minutes. Samples were drained and treated with αbungarotoxin-488 for 30 minutes for endplate visualization (green). Samples were
washed and mouse anti-neurofilament H and goat anti-GDNF primary antibodies
were applied for 4 days. Tissues were washed and donkey anti-goat-568 secondary
antibody was applied for 1 hour for GDNF visualization (red) along with donkey
anti-mouse-647 for neurofilament visualization (blue). Images were captured using a
Zeiss laser scanning confocal microscope. The images above depict increased GDNF
immunoreactivity in the region near the neuromuscular junction. Above top left
represents GDNF protein (red) and top right represents nAChRs (green). Above
bottom left represents neurofilament (blue) and above bottom right shows an overlay
of all three signals. These results suggest that GDNF protein is expressed at the NMJ
and possibly in the motor nerve bundle as well.
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GDNF is expressed at the NMJ in both EDL and SOL.

B

A

Figure 9. GDNF is expressed at the NMJ in both the EDL and SOL. The extensor
digitorum longus (A) (EDL) and soleus (B) (SOL) muscles were removed from four
week old male Sprague-Dawley rats. Whole EDL and SOL were too large to process
in a free-floating preparation so tissues were divided lengthwise into three and four
equal pieces respectively. The muscles were fixed using Zamboni’s fixative for 15
minutes. Tissues were treated with a blocking solution containing donkey serum for
30 minutes. Samples were drained and treated with α-bungarotoxin-488 (green) for
30 minutes for endplate visualization. Samples were washed and mouse antineurofilament H and rabbit anti-GDNF primary antibodies were applied for 4 days.
Tissues were washed and donkey anti-rabbit-568 secondary antibody was applied for
1 hour for GDNF visualization (red) along with donkey anti-mouse-647 for
neurofilament visualization (blue). Images were captured using a Zeiss laser
scanning confocal microscope.
The images above depict increased GDNF
immunoreactivity in the region near the neuromuscular junction. Both the EDL (A)
and the SOL (B) show a different pattern of expression of GDNF protein as compared
to the goat anti-GDNF antibody. The GDNF immunopositive regions appear to
follow the contours of the endplate region more closely and have a more definitive
border than previously observed with the goat anti-GDNF antibody. Also different is
the appearance of punctate labeling in regions away from the NMJ.
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While the rabbit antibody appeared to be increased near the region of the
NMJ, the GDNF labeling (Figure 9, red) appeared to follow the contours of the
endplate region more definitively. This was in stark contrast to the GDNF labeling
observed with the goat antibody (Figures 6, 7, and 8) where GDNF expression
appeared hazy around the region of the NMJ. This difference in GDNF protein
expression was also observed near the region of neurofilament positive staining
(Figures 7 and 8 [blue] compared to Figure 9 [blue]).
We also noticed that the second (rabbit) GDNF antibody appeared to
additionally label the samples in a more punctate manner away from the NMJ
(Figures 8 and 9 [red]). It was not clear whether this was specific labeling of the
GDNF molecule or non-specific binding of a different epitope.

When primary

antibody (rabbit) was omitted the punctate labeling was not present suggesting that
the punctate signals were not effects of the secondary antibody.
Together these results demonstrate that GDNF protein is expressed at the
region of the neuromuscular junction. We offer evidence that GDNF expression is
similar in rat skeletal muscle as it appears in human skeletal muscle. This is not
surprising considering that mature rat and human GDNF share a 93% overlap of
amino acid sequence. We have also demonstrated that two different types of GDNF
primary antibodies can label GDNF protein differently. This is also not surprising
considering that GDNF protein has two isoforms of expression.
Expression of GDNF, like other neurotrophic factors, has various isoforms. It
has been determined that GDNF mRNA has both an α- and a β- form and that both
isoforms are expressed in skeletal muscle (Springer et al. 1995; Trupp et al. 1995).
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When measured, the longer α-isoform had approximately 633 base pairs and the
shorter β-isoform had an identical sequence with a 78 base-pair deletion in the prepro
region. The GDNF protein accordingly also was expressed as two isoforms, the full
length protein being 211 amino acids and a mature protein isoform that is 26 amino
acids shorter. It could be that the two antibodies used may have differed in their
recognition epitope and since GDNF protein can be expressed in multiple isoforms,
then it follows that expression patterns can vary depending upon the antibody used.
Another interesting finding from our results was the observation that not
every endplate region was positive for increased GDNF protein expression.

It

appeared that possibly only a subset of skeletal muscle endplates might display
increased GDNF protein expression. We subsequently decided to attempt to identify
if there was any relationship between increased GDNF staining and skeletal muscle
fiber type.

Extrafusal Muscle Fibers
As mentioned in chapter two, we were interested in identifying the skeletal
muscle fiber-type composition of our tissues. Previous exercise and developmental
studies suggested a possible relationship between skeletal muscle composition and
changes in GDNF protein content. While the proportion of the specific skeletal
muscle fiber-types for each of the tissues has already been previously reported
(Ariano et al. 1973; Alnaqeeb and Goldspink 1987), we hoped to use skeletal muscle
fiber-type immunohistochemistry to identify any possible relationship with GDNF
protein expression in skeletal muscles. Our results of slow-myosin staining of the
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EDL, FDS and SOL (Figure 10) appear to match closely the published reports of
slow-twitch muscle fiber composition (2%, 8%, and 88% respectively).
One of the main objectives of skeletal muscle fiber-type staining was to
determine if there was any correlation with our previous findings of increased GDNF
protein expression at a subset of NMJs. We used antibodies directed against the slow
myosin isoform and the type IIA (fast, intermediate) myosin isoform and looked at
transverse sections of both the EHL and the EDL. We found that in the EHL the
muscle fibers with GDNF positive endplate regions did not positively stain for the
type IIA myosin antibody (Figure 11). However, these results do not conclusively
rule out a possible association between this muscle fiber-type and increased GDNF
immunoreactivity at the endplate since none of the endplates visualized were
associated with the type IIA skeletal muscle fibers.
Our results suggest that increased GDNF protein expression at the NMJ is not
solely limited to the fast-intermediate skeletal muscle fiber-type. It might be that
increased GDNF protein expression at the NMJ is associated with the fastintermediate skeletal muscle fiber-type in conjunction with other skeletal muscle
fiber-types. Future studies should be directed at identifying endplate regions on these
type IIA myosin immunopositive muscle fibers and determine the GDNF protein
expression at these NMJs. We decided to investigate the possibility of increased
GDNF protein expression at the NMJ of slow-twitch muscle fibers.
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Slow myosin staining for three hind limb skeletal muscles.

EDL

FDS

SOL

Figure 10. Slow myosin staining for three hind limb skeletal muscles. The extensor
digitorum longus (EDL), flexor digitorum superficialis (FDS), and soleus (SOL)
muscles were removed from four week old male Sprague-Dawley rats. Tissues were
removed and cut into 50 μm sections. Samples were fixed using Zamboni’s fixative.
Slides were washed and then treated with mouse anti-slow-myosin for 1 hour. Slides
were washed and secondary antibody directed against the primary antibody was
applied for 30 minutes for slow-twitch muscle fiber visualization (white). Images
were captured using a Zeiss laser scanning confocal microscope. The image above
depicts the relative composition of slow-twitch muscle fibers of each of the three
tissues. These images visually support the published values of 2, 8, and 88 percent of
slow-twitch muscle fibers for the EDL, FDS, and SOL respectively.
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GDNF is expressed at neuromuscular junctional regions that are
not associated with fast-intermediate myosin.

A

B

Figure 11. GDNF is expressed at neuromuscular junctional regions that are not
associated with fast-intermediate myosin. The extensor hallucis longus (EHL)
muscle was removed from four week old male Sprague-Dawley rats. The muscle was
cut into 500 μm sections and fixed using Zamboni’s fixative. Samples were treated
with a blocking solution containing donkey serum for 30 minutes. Slides were
drained and treated with α-bungarotoxin-488 for 4 hours for endplate visualization
(green). Samples were washed and goat anti-GDNF and mouse anti-typeIIA myosin
primary antibodies and were applied for 7 days. Slides were washed and donkey antigoat-568 and donkey anti-mouse-647 secondary antibodies were applied for 5 hours
for GDNF visualization (red) and fast-intermediate muscle fibers (blue). Images
were captured using a Zeiss laser scanning confocal microscope. The images above
depict increased GDNF immunoreactivity (red) in the region near the neuromuscular
junction (green). However, these GDNF positive endplate regions are not associated
with fast-intermediate muscle fibers (blue). In A above, three GDNF positive
endplate regions are visualized on muscle fibers that lack positive labeling of type
IIA myosin antibody. In B above, again GDNF positive endplates are visualized that
lack type IIA myosin labeling. However these results do not conclusively rule out a
possible association between fast intermediate muscle fiber-type and increased GDNF
immunoreactivity at the endplate since none of the endplates visualized were on the
type IIA skeletal muscle fibers.
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We found that GDNF protein expression was increased at the NMJs of slowtwitch skeletal muscle fibers (Figure 12). Nearby junctions that were not associated
with slow-myosin antibody either did not appear to have increased GDNF protein
expression associated with them, or the relative level of GDNF protein signal was
greatly diminished. One caveat is that these findings are preliminary in nature and
improved imaging as well as replication of this phenomenon is needed in order to be
stated conclusively. Future studies should be directed at replicating and improving
these preliminary findings.
While amidst our investigations into the increased GDNF signaling at the
neuromuscular junction, recent work suggested that the motor neuron subset that
responds most to functional down-regulation or up-regulation of GDNF expression
may be the motor neurons that synapse on intrafusal muscle fibers (Whitehead et al.
2005). We therefore decided to see if we could label these skeletal muscle fiber types
and determine if GDNF protein immunoreactivity is increased at their NMJs.
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GDNF is expressed at the neuromuscular junctions associated with slow
myosin.

Figure 12. GDNF is expressed at the neuromuscular junctions associated with slow
myosin. The extensor digitorum longus (EDL) muscle was removed from four week
old male Sprague-Dawley rats. The muscle was cut into 50 μm sections and fixed
using Zamboni’s fixative. Samples were treated with a blocking solution containing
donkey serum for 30 minutes. Slides were drained and treated with α-bungarotoxin488 for 30 minutes for endplate visualization (green). Samples were washed and goat
anti-GDNF and mouse anti-slow myosin primary antibodies were applied for 4 days.
Slides were washed and donkey anti-goat-568 and donkey anti-mouse-647 secondary
antibodies were applied for 1 hour for GDNF visualization (red) and slow myosin
labeling (blue). Images were captured using a Zeiss laser scanning confocal
microscope. The image above depicts increased GDNF immunoreactivity (red) in the
region near the neuromuscular junction (green) of a slow-myosin immunopositive
muscle fiber.
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Intrafusal Muscle Fibers
Until this point, our investigations involved identification of increased GDNF
protein expression in regards to extrafusal muscle fibers. Extrafusal muscle fibers are
the skeletal muscle fibers within a muscle that are responsible for the generation of
force associated with skeletal muscle contraction. These fibers make up the majority
of the composition of any given skeletal muscle. There exists another muscle fiber
population termed intrafusal muscle fibers.

These muscle fibers are part of a

specialized sensory apparatus and they do not contribute to the generation of skeletal
muscle force during contraction.
The main role of the intrafusal muscle fibers is as a sensory organ to detect
changes in skeletal muscle length to help regulate proprioception. These fibers are
often involved in reflex pathways and are important for sensing overall changes in
skeletal muscle position. They are also innervated by motor neurons. These motor
neurons regulate the tension in these intrafusal muscle fibers and keep the sensory
apparatus functional. As the extrafusal muscle fibers contract or relax the length of
the skeletal muscle changes accordingly. In order for these intrafusal muscle fibers to
be able to detect changes in tension, they also need to have the ability to contract and
relax as the muscle length changes.
Early investigations into GDNF expression in these intrafusal muscle fibertypes demonstrated an increased immunoreactivity in the muscle spindle and the
capsule that encloses the intrafusal muscle fibers in human skeletal muscle (Suzuki et
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al. 1998). It was not further investigated until Whitehead et. al. (2005) demonstrated
that using gene modification of GDNF expression that the changes observed in mouse
motor neuron populations with GDNF could be accounted for by changes in γ-motor
neuron populations (those that synapse with intrafusal muscle fibers) and that αmotor neuron populations (those that synapse with extrafusal muscle fibers) were not
significantly affected. We therefore decided to see if we could label these intrafusal
skeletal muscle fibers in rat and determine if GDNF is expressed in these fibers.
We found that GDNF protein was expressed in the intrafusal fibers of rat EDL
(Figure 13). When imaged using the rabbit anti-GDNF antibody, there was strong
immunopositive GDNF signaling within the muscle membrane. As previously noted,
this antibody appeared to label within the muscle fiber in a punctate manner. The
nearby extrafusal fibers did not stain strongly for GDNF protein within the muscle
fibers. However, a subset of extrafusal fibers did appear to contain GDNF within the
muscle fibers. These findings are similar to those presented by Suzuki et. al. (1998)
in human skeletal muscle biopsies.
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GDNF is expressed in intrafusal muscle fibers of rat skeletal muscle.

A

B

Figure 13. GDNF is expressed in intrafusal muscle fibers of rat skeletal muscle. The
extensor digitorum longus (EDL) muscle was removed from four week old male
Sprague-Dawley rats. The muscle was cut into 50 μm sections and fixed using
Zamboni’s fixative. Samples were treated with a blocking solution containing
donkey serum for 30 minutes. Slides were drained and treated with rabbit anti-GDNF
and mouse anti-s46 primary antibodies for 5 days. Slides were washed and donkey
anti-goat-488 and donkey anti-mouse-647 secondary antibodies were applied for 1
hour. Images were captured using a Zeiss laser scanning confocal microscope. For
both A and B above intrafusal muscle fibers are labeled using the mouse anti-s46
antibody (blue) and the rabbit anti-GDNF antibody (green). In A GDNF protein is
expressed in all of the s46-labeled intrafusal muscle fibers and in a subset of
extrafusal muscle fibers. In B a series of transverse images were reconstructed and
rotated to demonstrate GDNF labeling within the intrafusal muscle fibers in a
longitudinal view.
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Summary
We found that GDNF protein is expressed near the region of the
neuromuscular junction in rat skeletal muscle. Expression at the neuromuscular
junction did not appear to occur for all skeletal muscle fibers and we demonstrated
that NMJs of slow-twitch muscle fibers contain increased GDNF protein labeling.
We also demonstrated that GDNF protein is expressed in intrafusal muscle fibers of
rat skeletal muscle. Together these results further our understanding of how GDNF
protein is expressed in rat skeletal muscle.
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CHAPTER IV
GDNF WITH AGING
Introduction
Many changes occur with advanced skeletal muscle aging.

There is a

significant loss of skeletal muscle cross-sectional area termed, “sarcopenia,” where
by the process of aging, skeletal muscle loses approximately 1/3 its normal adult
weight (Rosenberg 1997). These changes are attributed to either a decrease in muscle
fiber diameter, a decrease in muscle fiber number, or a combination of both. While
some of the phenotypic changes in muscle fiber size can be attributed to decreased
satellite cell activity (Roubenoff and Hughes 2000; Edstrom and Ulfhake 2005),
others have observed a change in muscle fiber-type composition with age (Tauchi et
al. 1971; Larsson et al. 1978).
One of the main changes occurring with age that contributes to the
progression of sarcopenia is the loss of α-motor neurons. This leads to an overall
decrease of number of motor units by 50% in people over 60 years of age (Brown
1972; Brown et al. 1988; Roubenoff and Hughes 2000). This loss in motor unit
number is attributed to a selective denervation of fast twitch muscle fibers and
collateral reinnervation by motor neurons from nearby slow twitch fibers. This agerelated change in fiber type composition has been well studied (Tauchi et al. 1971;
Larsson et al. 1978; Alnaqeeb and Goldspink 1987). One possible explanation for the
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loss of motor neuron innervation with age could be due to altered neurotrophic factor
signaling with age (Bergman et al. 1999).
Neurotrophic factors are extra cellular signaling proteins that are important for
motor neuron survival. One of the most potent neurotrophic factors for peripheral
motor neurons is glial cell line-derived neurotrophic factor (GDNF) (Henderson et al.
1994). GDNF is critical for proper motor neuron development and alterations in
GDNF levels can have effects on early motor neuron survival (Henderson et al. 1994;
Oppenheim et al. 1995; Yan et al. 1995; Nguyen et al. 1998; Keller-Peck et al. 2001;
Zwick et al. 2001; Nagano and Suzuki 2003). While the role of GDNF in skeletal
muscle in early development has been extensively examined, little is known about the
role of GDNF in skeletal muscles with age.
The previous studies focus primarily on changes in GDNF observed in early
(pre to early post-natal) development. Studies that do involve adult organisms are
generally intended to observe changes in GDNF in response to exercise, motor
neuron damage, or motor neuron disease (Lie and Weis 1998; Chen et al. 2001; Wang
et al. 2002; Wehrwein et al. 2002; Dupont-Versteegden et al. 2004). It is the purpose
of this study to examine the GDNF protein content of skeletal muscles beyond the
early post-natal time point, through adulthood, and into the later stages of skeletal
muscle aging. A better understanding of how GDNF is expressed in skeletal muscle
with age might provide insight as to its possible role in age-associated neurological
changes that occur.
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Materials and Methods

Animals
Male Sasco Sprague Dawley rats were housed with free access to food and
water and maintained in accordance with the institutional animal care and use
committee standards. Two separate analyses were performed; the first contained
animals at 5, 7, 9, 14, and 19 months of age (n = 8,6,5,6,5 respectively). Within this
group; the extensor digitorum longus (EDL) and flexor digitorum superficialis (FDS)
muscles were removed for all time points and the vastus intermedius (VI) muscles
were removed from the 7, 9, and 19 month groups. For the second study; EDL, FDS,
and soleus (SOL) muscles were removed from animals at 1, 10, and 23 months of age
(n = 5,8,5 respectively).

Tissue Processing
Tissues were removed and frozen on dry ice. To determine GDNF protein
content, samples were subsequently dipped in liquid nitrogen and smashed into a fine
powder. Sample processing buffer (0.4 M NaCl, 2 mM EDTA, 0.1 mM
benzethonium chloride, 2 mM benzamidine, 20 KIU/ml aprotinin, 0.5% BSA, 0.05%
Tween-20 in PBS) was added and the mixture was homogenized on ice. Samples
were then centrifuged for 30 min at 4ºC and supernatant collected and stored at 80ºC. GDNF protein content of the supernatant was determined using enzyme-linked
immunosorbant assay (ELISA).
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For the first study, samples were prepared at a 1:4 dilution of tissue weight (in
mg) to sample buffer volume (in mL). In the second study, samples were prepared at
a 1:14 tissue weight to buffer volume dilution.

All of the ELISA sample

concentration values were multiplied by their respective dilution factor to determine
total GDNF and then normalized to tissue weight and represented as pg of GDNF/mg
tissue weight.

Enzyme-linked Immunosorbant Assay
Enzyme-linked immunosorbant assays were performed using capture antibody
(R&D Systems, MAB212) and detection antibody (R&D Systems, BAF212) to
manufacturer’s specifications (R&D Systems).

The tetramethylbenzidine color

reagent (Sigma, T-3405) was prepared according to manufacturer specifications. The
reaction was stopped with 0.1 M phosphoric acid and absorbance measured at 450
nm.

Data Analysis and Statistics
Data were analyzed using the Kruskal-Wallis analyses of ranks procedure
followed by the non-parametric multiple comparisons analysis published by (Simes
1986). Significance was established at p ≤ 0.05 for all comparisons and all values
reported as GDNF pg/mg tissue weight ± SEM.
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Results
For the first study, GDNF values were analyzed from rats of 5, 7, 9, 14, and
19 months of age (n = 8,6,5,5,5, respectively). The oldest animals had significantly
more GDNF protein content than the mid-age time points while the youngest group
seemed to be only slightly elevated but not statistically significant. For the FDS, the
19 month old group (0.628 ± 0.15 pg/mg) had significantly more GDNF protein
content than the 5, 7, 9, and 14 month groups (0.164 ± 0.05, 0.024 ± 0.01, 0.058 ±
0.03, and 0.073 ± 0.07 pg/mg tissue respectively) (Figure 14). For the EDL the 19
month time point (0.560 ± 0.10 pg/mg tissue) also had significantly more GDNF than
the 5, 7, 9, and 14 month old groups (0.119 ± 0.06, 0.042 ± 0.02, 0.021 ± 0.01, and
0.123 ± 0.08 pg/mg tissue respectively) (Figure 15). The VI also followed this trend
and the 19 month time point (3.01 ± 0.72 pg/mg tissue) had significantly more GDNF
protein than both the 7 month (0.450 ± 0.23 pg/mg tissue) and the 9 month (0.447 ±
0.23 pg/mg tissue) old groups (Figure 16).
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GDNF protein content of the FDS is highest at 19 months
of age.
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Figure 14. GDNF protein content of the FDS is highest at 19 months of age. Glial
cell line-derived neurotrophic factor (GDNF) protein values of rat flexor digitorum
superficialis (FDS) at various time points with age. Male Sprague-Dawley rats were
euthanized at various ages and GDNF protein content of the FDS was measured using
standard ELISA procedures. GDNF was highest at the latest time point of 19 months
of age and significantly elevated when compared to all other ages sampled. For the 5,
7, 9, 14, and 19 month groups n = 8,6,5,5,5, respectively. (* significantly different
from all other groups, p ≤ 0.05)
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GDNF protein content of the EDL is highest at 19 months
of age.
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Figure 15. GDNF protein content of the EDL is highest at 19 months of age. Glial
cell line-derived neurotrophic factor (GDNF) protein values of rat extensor digitorum
longus (EDL) at various time points with age. Male Sprague-Dawley rats were
euthanized at various ages and GDNF protein content of the EDL was measured
using standard ELISA procedures. GDNF was highest at the latest time point of 19
months of age and significantly elevated when compared to all other ages sampled.
For the 5, 7, 9, 14, and 19 month groups n = 8,6,5,5,5, respectively. (* significantly
different from all other groups, p ≤ 0.05)
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GDNF protein content of the VI is highest at 19 months
of age.
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Figure 16. GDNF protein content of the VI is highest at 19 months of age. Glial cell
line-derived neurotrophic factor (GDNF) protein values of rat vastus intermedius (VI)
at various time points with age. Male Sprague-Dawley rats were euthanized at
various ages and GDNF protein content of the VI was measured using standard
ELISA procedures. GDNF was highest at the latest time point of 19 months of age
and significantly elevated when compared to both the 7 and 9 month time points. For
the 7, 9, and 19 month groups n = 6,5,5, respectively. (* significantly different from
all other groups, p ≤ 0.05)

58

In the second study, GDNF values were analyzed from animals at 1 month,
10 month, and 23 months of age ( n = 5 for all groups). There were no significant
differences in GDNF protein content in the EDL at any time point (Figure 17). In the
FDS, GDNF protein content significantly decreased between 1 month (47.9 ± 6.5
pg/mg tissue) and 10 months (20.8 ± 4.5 pg/mg tissue) of age and significantly
increased between 10 months and 23 months (35.2 ± 1.7 pg/mg tissue) of age (Figure
18). There was no significant difference in the GDNF protein content of the FDS
between the 1 month and the 23 month time points. For the SOL, GDNF protein
levels were significantly elevated at 1 month (96.5 ± 11.6 pg/mg tissue) compared to
10 months (41.9 ± 6.9 pg/mg tissue) of age and compared to the 23 month (65.0 ± 6.6
pg/mg tissue) old group. The 23 month old group GDNF protein content was also
significantly elevated compared to the 10 month old time point (Figure 19).
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GDNF protein content of the EDL remains constant
with age.
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Figure 17. GDNF protein content of the EDL remains constant with age. Glial cell
line-derived neurotrophic factor (GDNF) protein values of rat extensor digitorum
longus (EDL) at various time points with age. Male Sprague-Dawley rats were
euthanized at various ages and GDNF protein content of the EDL was measured
using standard ELISA procedures. GDNF protein content did not significantly differ
at any of the time points sampled. For the 1, 10, and 23 month groups n = 5, 8, and 5
respectively.
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GDNF protein content of the FDS fluctuates with
age.
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Figure 18. GDNF protein content of the FDS fluctuates with age. Glial cell linederived neurotrophic factor (GDNF) protein values of rat flexor digitorum
superficialis (FDS) at various time points with age. Male Sprague-Dawley rats were
euthanized at various ages and GDNF protein content of the FDS was measured using
standard ELISA procedures. GDNF protein content significantly decreased from 1
month of age (47.9 ± 6.5 pg/mg tissue, n = 5) to 10 months (20.8 ± 4.5 pg/mg tissue,
n = 8 [* p ≤ 0.05]). GDNF protein content significantly increased between 10 months
of age and 23 months of age (35.2 ± 1.7 pg/mg, n = 5 [ # = significantly different than
previous group, p ≤ 0.05)]).
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GDNF protein content of the SOL fluctuates with
age.
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Figure 19. GDNF protein content of the SOL fluctuates with age. Glial cell linederived neurotrophic factor (GDNF) protein values of rat soleus (SOL) at various
time points with age. Male Sprague-Dawley rats were euthanized at various ages and
GDNF protein content of the SOL was measured using standard ELISA procedures.
GDNF protein content significantly decreased between 1 month (96.5 ± 11.6 pg/mg
tissue) and 10 months of age (41.9 ± 6.9 pg/mg tissue). GDNF significantly
increased between 10 months and 23 months of age (65.0 ± 6.6 pg/mg tissue). At 23
months of age, the SOL had significantly more GDNF than at 10 months of age, but
significantly less than at 1 month of age. For the 1, 10, and 23 month groups n = 5, 8,
and 5 respectively. (* = significantly different from all other groups, p ≤ 0.05)
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Comparisons were also made at each time point between the different
muscles. At 1 month of age (n = 5), GDNF protein content was significantly higher
in the SOL (96.5 ± 11.6 pg/mg tissue) than the EDL (37.2 ± 1.7 pg/mg tissue) and the
FDS (47.9 ± 6.5 pg/mg tissue) (Figure 20). At 10 months of age ( n = 8), GDNF
protein content in the FDS (20.8 ± 4.5 pg/mg tissue) is significantly less than in the
SOL (41.9 ± 6.9 pg/mg tissue) and EDL (37.2 ± 4.7 pg/mg tissue) (Figure 21). At the
23 months of age (n = 5), GDNF protein content was again significantly higher in the
SOL (65.0 ± 6.6 pg/mg tissue) than the EDL (29.3 ± 5.2 pg/mg tissue) and the FDS
(35.2 ± 1.7 pg/mg tissue) (Figure 22).
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The SOL contains significantly more GDNF protein
than the EDL and FDS at 1 month of age.
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Figure 20. The SOL contains significantly more GDNF protein than the EDL and
FDS at 1 month of age. Glial cell line-derived neurotrophic factor (GDNF) protein
values of rat hind limb skeletal muscle at one month of age. Male Sprague-Dawley
rats (n = 5) were euthanized at one month of age and GDNF protein content of 3
different hind limb skeletal muscles were measured using standard ELISA
procedures. GDNF was significantly increased in the soleus (SOL [96.5 ± 11.6
pg/mg tissue]) when compared to the extensor digitorum longus (EDL [37.2 ± 4.7
pg/mg tissue]) and the flexor digitorum superficialis (FDS [47.9 ± 6.5 pg/mg tissue])
at one month of age. (* = significantly different from all other groups, p ≤ 0.05)
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The FDS contains significantly less GDNF protein
than the SOL and EDL at 10 months of age.
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Figure 21. The FDS contains significantly less GDNF protein than the SOL and EDL
at 10 months of age. Glial cell line-derived neurotrophic factor (GDNF) protein
values of rat hind limb skeletal muscle at 10 months of age. Male Sprague-Dawley
rats (n = 8) were euthanized at 10 months of age and GDNF protein content of 3
different hind limb skeletal muscles were measured using standard ELISA
procedures. GDNF was significantly decreased in the flexor digitorum superficialis
(FDS [20.8 ± 4.5 pg/mg tissue]) when compared to the extensor digitorum longus
(EDL [40.0 ± 2.9 pg/mg tissue) and to the soleus (SOL [41.9 ± 6.9 pg/mg tissue]). (*
= significantly different from all other groups, p ≤ 0.05)
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The SOL contains significantly more GDNF protein
than the EDL and FDS at 23 months of age.
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Figure 22. The SOL contains significantly more GDNF protein than the EDL and
FDS at 23 months of age. Glial cell line-derived neurotrophic factor (GDNF) protein
values of rat hind limb skeletal muscle at 23 months of age. Male Sprague-Dawley
rats (n = 5) were euthanized at 23 months of age and GDNF protein content of 3
different hind limb skeletal muscles were measured using standard ELISA
procedures. GDNF was significantly increased in the soleus (SOL [65.0 ± 6.6 pg/mg
tissue]) when compared to the extensor digitorum longus (EDL [29.3 ± 5.2 pg/mg
tissue]) and the flexor digitorum superficialis (FDS [35.2 ± 1.7 pg/mg tissue) at 23
months of age. (* = significantly different from all other groups, p ≤ 0.05)
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Discussion

Between Study Comparisons
When comparing the results of these two studies there is a discrepancy in the
reported GDNF protein content values. The range of mean values of the first study
span from 0.021 ± 0.01 to 3.01 ± 0.72 pg/mg tissue while the range of the second
study is between 20.8 ± 4.5 and 96.5 ± 11.6 pg/mg tissue. When comparing relative
time point values for the EDL between the two studies this becomes even more
apparent. The first study found GDNF protein content in the EDL of the 9 month old
group to be 0.021 ± 0.01 pg/mg tissue. This is significantly less than the GDNF value
of the EDL in the 10 month old group of the second study (37.2 ± 4.7 pg/mg tissue).
The reason for this discrepancy might be a result of the differences in the way the
samples were processed.
The samples in the first study were processed at a 1:4 ratio of tissue weight (in
mg) : volume of sample buffer (in mL). The samples of the second study were
processed at a 1:14 dilution factor. These results demonstrate a significantly different
expression of GDNF protein content from similarly age-matched EDL. This might
have been a result of a differential extraction of GDNF from the tissue during sample
processing.

The data suggests that there may be an optimal dilution factor for

extraction of GDNF from skeletal muscle, although future investigation is warranted
to directly determine this effect.

It is because of the suggested discrepancy in

extraction ability, further comparisons were not made among absolute values of
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GDNF protein content between the two studies. Instead, significant changes in GDNF
protein content within each study were determined and results were compared with
respect to the process of aging.

Early to Midlife Comparisons
The general trend of GDNF protein expression early in life appeared to be the
same between the two studies. Early life (1 and 5 month) time points were either
significantly elevated or only slightly elevated from the midlife (7, 9, 10, and 14
month) time points. This could possibly be a continuation of elevated expression
from increased GDNF levels in early development.

Nagano and Suzuki (2003)

determined that GDNF protein content for the SOL of Wistar rats significantly
increased from postnatal day 6 to postnatal day 15, was highest at 1 month of age,
and significantly decreased by 3 months of age. Our results demonstrate this similar
developmental trend. GDNF protein content of the SOL peaked at 1 month of age
and was significantly higher than at 10 months of age (Figure 19). Taken together
these results suggest that GDNF protein content in the SOL increases in early
development, peaks at 1 month of age, and subsequently decreases into adulthood.
These early trends in GDNF protein expression of the SOL follow
developmentally important time points. During the first two postnatal weeks, the
neuromuscular junction (NMJ) is undergoing both pre- and post-synaptic changes in
order to stabilize the neuromuscular communication. It has been demonstrated that
after the first two postnatal weeks the gross structure of the NMJ remains stable and
that only the overall size of the junction changes with proportion to the growth of the
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muscle fibers (Balice-Gordon and Lichtman 1990). These normal changes that occur
with growth and development involve a three-fold increase in size. Growth occurs
until approximately 18-weeks of age and the NMJ remains relatively stable unless
influenced by exercise, disuse, microgravity, or aging (for review see (Wilson and
Deschenes 2005). It is interesting then, that both our results and the results of
Nagano and Suzuki (2003) demonstrate that GDNF protein content of the SOL is
highest shortly after the NMJ is stabilized and declines during the time of the threefold increase in NMJ size between one and three months of age.
As for the FDS and EDL, there can be no direct comparisons made from
Nagano and Suzuki (2003) since they only examined changes in GDNF protein
content for the SOL and gastrocnemius (GAST). They did, however, demonstrate a
difference in GDNF protein expression between the SOL and GAST in early
postnatal development. They determined that while GDNF in the SOL was low
initially (increased from postnatal day 6 to 1 month and then decreased from 1 to 3
months), in the GAST the pattern was almost the opposite. GDNF was elevated
initially, decreased from postnatal day 6 to 15, remained unchanged through 1 month
and then increased between 1 and 3 months of age. This observed difference in
expression between different skeletal muscle tissue types was also present in our
studies.
In the EDL, there was no significant difference when comparing any of the
early life time points to any of the midlife for either of our two studies (Figures 15
and 17). This is different than the changes observed with the SOL and different still
from the observations made by Nagano and Suzuki (2003) in the GAST. These
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results support the suggestions that various hind limb skeletal muscles display
differential expression patterns of GDNF protein content in early life and midlife.
The results from the FDS were similar in its pattern of expression of early and
midlife GDNF protein content to that of the SOL but with a significantly smaller
magnitude. In the first study GDNF protein content was unchanged from months 5 to
14 months of age (Figure 14). The second study demonstrated a significant decrease
from 1 month to 10 months of age (Figure 18). This early to midlife decrease in
GDNF protein content appears to occur only in the SOL and FDS while the GDNF
protein content of the EDL does not significantly change throughout any of these
early time points.
One possible explanation for these inherent differences in GDNF protein
content could be based upon skeletal muscle fiber type. When comparing the relative
composition of these three tissues the SOL contains the highest percentage of slow
muscle fibers (88%), the EDL contains the least (2%), and the FDS composition is
slightly more slow than the EDL (8%) (Ariano et al. 1973; Alnaqeeb and Goldspink
1987). The SOL and FDS both had similar changes in GDNF protein content with
age, but at every time point the concentration in the SOL was significantly higher
than the FDS (Figures 20, 21, and 22). This discrepancy might also be explained by
the inherent differences in their fiber type composition.
Tissues with elevated slow muscle fiber-type composition appear to change in
GDNF protein content while tissues that have relatively low numbers of slow muscle
fibers did not show any changes in early to midlife development. However, the
results with GDNF protein content are only correlative to skeletal muscle fiber type
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and may possibly be explained by other differences between these skeletal muscles.
Future studies aimed to directly examine the relationship between skeletal muscle
fiber type and GDNF protein expression are warranted.
It is also important to note that while the results from the vastus intermedius
(VI) muscle are reported (Figure 16), there were technical difficulties in successful
removal of this tissue. The VI was chosen as it was a good candidate to represent a
muscle with an evenly mixed muscle fiber type composition; however dissection of
this tissue was inconsistent throughout. Due to its direct insertion into the medial
femur and unclear borders with neighboring quadriceps muscles, tissues were often
damaged during removal and/or included pieces of the neighboring vastus lateralis
and vastus medialis. It is because of these technical issues that the results from the
VI are presented here but are not discussed in great detail.

Late Life Comparisons
Another aging trend in GDNF protein expression appears late in life. We
analyzed changes in GDNF protein content in the late life stages (19 and 23 months)
in both of our studies. One might suggest that a possible cause for the denervation of
muscle fibers and subsequent fiber type change that occurs with sarcopenia could be
due to a decrease in the neurotrophic protein supplied to the nerves by the target
tissues. Here we demonstrate that throughout the late life stages GDNF protein
content either significantly increased or had no change from the previous midlife
values. None of the skeletal muscles examined displayed decreased GDNF protein
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content with advanced aging. This might be explained by comparing the neurological
changes that occur in skeletal muscle during this time frame.
Skeletal muscle changes in senescence include denervation of fast muscle
fibers followed by partial re-innervation of fast muscle fibers by neighboring slow
motor neurons. However, the re-innervation process does not occur for all of the
denervated fast muscle fibers and slowly these muscle fibers are lost and overall
skeletal muscle size and motor unit numbers are decreased.

Others have

demonstrated that denervation is a cue for increased GDNF expression (Lie and Weis
1998; Chen et al. 2001). It could be that the significant increases that we observe
with our latest time point are a result of increased denervation with age. It is
important to note that while GDNF protein levels do not decrease with age GDNF
signaling might still be affected.
Bergman et. al. (1999) determined that the GDNF receptor alpha-1 (GFRα1)
and co-receptor c-ret mRNA significantly increased in motor neurons from SpragueDawley rats at 30 months of age compared to 2-3 months of age. They also noted
that of the motor neurons that increased GFRα1 mRNA expression, a subpopulation
of motor neurons (25%) appeared to display very high levels of GFRα1 mRNA.
These aged animals also exhibited a significant increase in protein expression
observed via immunohistochemistry. Taken together these results suggest that even
though GDNF protein content increases or remains constant with age, GDNF
signaling might be affected by a change in GDNF receptor. Therefore, even without
significant changes in GDNF protein content GDNF may still be a factor involved in
the denervation observed with sarcopenia. Additionally, our observations are merely
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correlative with the aging process and did not attempt to identify neurological signs
of aging.

Future studies should include identification and quantification of the

denervation process with aging and the response of GDNF protein expression in
respect to aging.
There was an interesting conflict of results between our two studies in the
EDL with age. The first study demonstrated a significant increase in GDNF protein
content at 19 months of age (Figure 15) while the second study showed no significant
change from 10 months when compared to 23 months of age (Figure 17). It could be
that for this tissue GDNF undergoes a series of significant changes between 10 and
23 months of age, including a significant increase at 19 months and an eventual
decrease at 23 months. This would be quite different than the results observed with
SOL and FDS that were both significantly higher at 19 months and remained
significantly elevated at 23 months. The EDL is composed primarily of fast-twitch
muscle fibers and age related changes in skeletal muscle composition have been
shown to preferentially affect fast-twitch muscle fibers.

Further information is

needed to clarify if the differences observed in the EDL between the first and second
study are in fact real differences or if they are artifact due to the different extraction
methods used between the two studies.

73

Summary
We have examined the effects of aging on GDNF protein content of three
different hind limb skeletal muscles. We have determined that the SOL and EDL
contain significantly different basal levels of GDNF protein content. These inherent
tissue differences may be related to differences in skeletal muscle fiber-type
composition. We have also determined that GDNF protein expression changes with
age and that these changes do not appear to be uniform for all muscle types. These
changes overlap and might well be associated with neurological events that occur
with early development and aging. These findings further characterize how GDNF
protein expression is affected with aging and may provide insight as to GDNF’s
possible role in neurological changes that occur in skeletal muscle with age.
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CHAPTER V
GDNF WITH VOLUNTARY RUNNING
Introduction
Glial cell-line derived neurotrophic factor (GDNF) was first discovered in the
brain and found to promote survival and differentiation in dopaminergic neurons (Lin
et al. 1993). Further investigation determined that GDNF is critical for proper motor
neuron development (Henderson et al. 1994). Over expression of GDNF in skeletal
muscle in transgenic mice resulted in hyper-innervation of the neuromuscular
junction (Zwick et al. 2001). Exercise after nerve injury has been shown to increase
GDNF mRNA and speed the time of recovery after injury in the rat soleus (SOL)
muscle (Dupont-Versteegden et al. 2004).
A recent study in our laboratory demonstrated that GDNF protein expression
is regulated in an activity-dependent manner in normal, adult rat skeletal muscle
(Wehrwein et al. 2002). We determined that rats exercised by walk training had an
increase in GDNF protein in the SOL and the gastrocnemius (GAST) hind limb
skeletal muscles.

However, the use of negative reinforcement as a means for

motivation in this study might have increased stress and possibly affected GDNF
protein levels in these tissues.
We also noticed that while both the SOL and the GAST had significantly
increased in response to forced treadmill running, the SOL had a greater increase in
GDNF protein content in response to exercise than did the GAST. Additionally, the
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SOL from sedentary animals contained more GDNF protein content than the GAST
from sedentary animal. This suggests that there might be inherent differences in
skeletal muscles that could affect GDNF protein content and that not all muscles may
respond the same to exercise.
It is the purpose of this study to evaluate the effects of voluntary running on
GDNF protein content in skeletal muscle without the use of negative reinforcement.
We also intend to determine if changes in GDNF protein content are uniform for all
skeletal muscles or if individual muscles respond in individual manners.

We

hypothesize that GDNF protein content will be altered by voluntary running and that
the response to physical activity will vary depending upon the skeletal muscle
sampled.
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Materials and Methods
Male Fisher 344 rats (8 weeks old) were housed with free access to food and
water and maintained in accordance with the institutional animal care and use
committee standards. Four animals were housed in standard cages without access to
a running wheel and composed the sedentary control group. The remaining 8 animals
were allowed access to voluntary running wheels for 3 weeks. At the end of 3 weeks,
the 8 animals were not granted access to running wheels for 1 week. A subset of 4
animals was then re-allowed access to the voluntary running wheels for an additional
48 hours.
All animals were euthanized via CO2 asphyxiation followed by thoracotomy.
The extensor digitorum longus (EDL) and flexor digitorum superficialis (FDS)
muscles were removed and frozen on dry ice. Tissues were processed following
standard procedures in preparation for determination of GDNF protein content using
an enzyme-linked immunosorbant assay (R&D Systems, Minneapolis, MN). GDNF
protein values were quantified and expressed as pg/mg of tissue weight.
Data were analyzed using the one-way analysis of variance procedure
followed by the Student-Neuman-Keuls’ post hoc procedure.

Significance was

established at p ≤ 0.05 for all comparisons and all values reported as GDNF pg/mg
tissue weight ± SEM.
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Results
After 3 weeks of voluntary running and one week of rest, GDNF protein
levels in rat EDL (Figure 23) were significantly lower (18.1 ± 0.9 pg GDNF/mg
tissue, n = 4) than those of sedentary control animals (24.3 ± 1.0 pg GDNF/mg tissue,
n = 4). This significant decrease in GDNF protein expression is contrary to the
significant increase observed previously with forced treadmill running (Wehrwein et
al. 2002).
The second bout of 48 hours of voluntary running did not have any significant
effect on GDNF protein levels for the EDL (18.4 ± 1.7 pg GDNF/mg tissue, n = 4) as
compared to the exercised group (Figure 23). These animals did run voluntarily
during this time frame and at the same daily rate as before the stoppage.
In the FDS there was no significant difference in GDNF protein content
between the 3 week exercised and one week rest group (13.4 ± 0.4 pg GDNF/mg
tissue, n = 4) than that of the sedentary control group (15.2 ± 1.3 pg GDNF/mg tissue,
n = 4 [Figure 24]).
Similar to the EDL, the second bout of 48 hours of voluntary running did not
have any significant effect on GDNF protein levels for the FDS (15.2 ± 0.6
GDNF/mg tissue, n = 4) as compared to either of the other two groups (Figure 24).
These animals did run voluntarily during this time frame and at the same daily rate as
before the stoppage.

78

Effects of Voluntary Running on GDNF Protein Content
in Rat EDL.
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Figure 23. Effects of voluntary running on GDNF protein content in rat EDL. Three
weeks of voluntary running decreases GDNF protein expression in rat extensor
digitorum longus (EDL) muscles. Fisher 344 rats were housed with free access to
running wheels. After three weeks of running and one week of rest GDNF protein
content in EDL of the exercised group (EX, n=4) was significantly less (*p≤0.05)
than that of age-matched sedentary controls (SED, n=4). A subset of the exercised
group was then granted access again to the running wheels for 48 hours (EX+48,
n=4) to determine if there were any effects of a secondary acute bout of running. The
acute bout of running had no significant effect on GDNF protein levels of the EDL.
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Effects of Voluntary Running on GDNF Protein Content
in Rat FDS.
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Figure 24. Effects of voluntary running on GDNF protein content in rat FDS. Three
weeks of voluntary running had no significant effect on GDNF protein content in rat
flexor digitorum superficialis (FDS) muscles. Fisher 344 rats were housed with free
access to running wheels. After three weeks of running and one week of rest, there
was no significant effect on GDNF protein content in FDS of the exercised group
(EX, n=4) compared to age-matched sedentary controls (SED, n=4). A subset of the
exercised group was granted access again to the running wheels for 48 hours (EX+48,
n=4) to determine if there were any effect of a secondary acute bout of running. The
acute bout of voluntary running had no significant effect on GDNF protein levels of
the FDS.
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Discussion
We have demonstrated that voluntary running is able to alter GDNF protein
content in hind limb skeletal muscle. Our observations demonstrate the ability of
voluntary running to enact an activity dependent change in GDNF protein content in
rat skeletal muscle. Our results oppose, in direction, the previous results attained
with forced treadmill running. This discrepancy in the direction of change could be
due to differences in exercise protocols or the differences between muscles that were
analyzed.
While the EDL had a statistically significant decrease in GDNF protein, the
FDS showed no change with exercise. One explanation for these differences could be
based on the different composition of these two muscles. Others have demonstrated
that GDNF mRNA and protein content differs during development in various hind
limb skeletal muscles (Nagano and Suzuki 2003). They suggested that observed
differences may be due to inherent differences in skeletal muscle composition
including skeletal muscle fiber type. These inherent differences could be a possible
explanation as to why the FDS exhibited a greater response to voluntary exercise as
FDS has a greater percentage of slow muscle fiber type as compared to EDL
(unpublished observations). This might also account for the differences in direction
of change between this study and our previous findings.
When comparing the combined results of this study and our previous study, a
correlation may be drawn to fiber type composition. It has been established that the
EDL and the SOL are skeletal muscle opposites in many regards. They differ vastly
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in fiber-type composition, physiological function, neuronal activity patterns, and
metabolic activity, and it is because of these differences that they are chosen as some
of the most classically studied skeletal muscles (Alnaqeeb and Goldspink 1987; Reid
et al. 2003; Patterson et al. 2006). The SOL is composed primarily of slow-twitch
muscle fibers which make up 88% of the total fiber-type composition (Alnaqeeb and
Goldspink 1987). The EDL conversely, is composed primarily of fast-twitch muscle
fibers and only 2% of the muscle fibers are slow-twitch fibers (Alnaqeeb and
Goldspink 1987). The FDS is composed primarily of fast-twitch muscle fibers and
8% of the muscle fibers are slow-twitch fibers (Ariano et al. 1973). In the EDL,
GDNF protein content significantly decreased with exercise while in the SOL, GDNF
protein content significantly increased (Wehrwein et al. 2002). In the FDS exercise
did not elicit a significant change in GDNF protein content. This might suggest a
correlation with muscle fiber type such that the primarily fast-twitch EDL had a
significant decrease and the primarily slow-twitch SOL had a significant increase in
GDNF protein content in response to exercise. However, these results are only
observations made through correlation and may not be the only explanation for the
differential responses between these three skeletal muscles. Further investigation is
warranted to specifically address this possibility.
We were also interested in further characterizing the effect of exercise on
GDNF protein content. It could be possible that the change in GDNF protein content
observed previously with treadmill running was a transient effect and one that may
have attenuated shortly after inactivity. It is because of this that we chose to exercise
the animals for 3 weeks followed by 1 week of rest, as opposed to measuring GDNF
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immediately after the end of the running protocol. We were able to determine that
GDNF protein levels in the EDL still remained significantly different than in
sedentary controls even after one week of inactivity. This suggests that the change in
GDNF protein expression is not a transient effect but rather a lasting effect that was
still observed a week after cessation of exercise.
We also aimed to further characterize the effects of exercise on the regulation
of GDNF protein in skeletal muscle. After the one week of rest a subset of the
voluntary exercise group was granted access to running wheels for an additional 48
hours to determine the acute effect of exercise on GDNF protein levels. This second
bout of acute activity demonstrated that GDNF protein levels could not be
significantly altered within this short time frame. This provides further support that
GDNF protein expression is not regulated in a transient manner under these
conditions.
One possible argument could be that the ability of skeletal muscle to alter
GDNF protein content in response to exercise might have already reached a
physiological plateau. It may be that any exercise beyond this point may not be
physiologically capable of further altering GDNF protein content. Future studies
should be intended to address not only this aspect, but to additionally characterize
this effect in a time-course study with the hopes to identify when GDNF is first
significantly altered by exercise, the physiological range of this response, and the
longevity of the effect of exercise on GDNF protein content in rat skeletal muscle.
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Summary
Together these results further our understanding of the physiology that
regulates GDNF expression in skeletal muscle in vivo. We have determined that
voluntary running can alter GDNF protein content and that these changes are not
transient in nature. We have also determined that voluntary running affects GDNF
protein content of the FDS different from EDL and suggest that individual muscles
may respond differently to increased physical activity.
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CHAPTER VI
BATH STUDIES
Introduction
GDNF was discovered in 1993 during a search for a neurotrophic factor for
dopaminergic neurons in the central nervous system (CNS) (Lin et al. 1993). Since
its discovery in CNS glial cells, GDNF mRNA has been identified in a variety of
tissues throughout the body (Suter-Crazzolara and Unsicker 1994). The protein is
important for dopaminergic neurons of the CNS, as well as many other neuronal
populations (Buj-Bello et al. 1995). One neuronal population in particular that is
affected by GDNF are motor neurons (MNs) of the peripheral nervous system that
innervate skeletal muscle (Henderson et al. 1994; Oppenheim et al. 1995).
GDNF has been shown to be one of the most potent neurotrophic factors for
MNs. Treatment with GDNF has rescued MNs from axotomy-induced cell death
(Oppenheim et al. 1995), slowed the loss of MNs in mice exhibiting progressive
motor neuropathy (Sagot et al. 1996), and protected MNs in a model of chronic motor
neuron degeneration (Corse et al. 1999). Alterations in GDNF expression have been
observed in skeletal muscle from humans with amyotrophic lateral sclerosis
(Yamamoto et al. 1996), polymyositis, and Duchenne type muscular dystrophy
(Suzuki et al. 1998).
Neurotransmitters have been shown to affect neurotrophic factor expression.
In vascular and bladder smooth muscle cells in culture, neurotransmitters from
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sympathetic neurons altered production of nerve growth factor by smooth muscle
cells (Spitsbergen et al. 1995; Clemow et al. 1999). In a previous study, Oppenheim
et al. (2000) demonstrated that blockade of nicotinic acetylcholine receptors on
skeletal muscle enhanced the survival of developing MNs in vivo. Others have
demonstrated that denervated skeletal muscle contains elevated levels of GDNF
mRNA (Lie and Weis 1998) suggesting that absence of neuronal influence leads to an
elevated GDNF mRNA response in skeletal muscle.
One possible explanation is that the release of the neurotransmitter
acetylcholine (ACh) from the intact nerve terminal and subsequent nicotinic
acetylcholine receptor (nAChR) activation decreases GDNF protein expression in
skeletal muscle. If this were the case, then extrinsic cues that lead to release of ACh
and subsequent nAChR activation may decrease GDNF expression in skeletal muscle.
It is the purpose of this study to determine how skeletal muscle activity may affect the
short-term response of GDNF expression in skeletal muscle and establish the possible
role of the nAChR in this response.
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Materials and Methods

Animals
Male SASCO Sprague-Dawley (Charles River, Kalamazoo, MI) were given
access to food and water ad libitum and maintained on a 12h light/dark cycle. Rats
(4wk, 100g ± 22g) were euthanized via CO2 asphyxiation followed by thoracotomy.

Bath Studies
Bilateral soleus (SOL), flexor digitorum superficialis (FDS), and extensor
digitorum longus (EDL) were removed and placed into a tissue bath containing
Krebs-Ringer bicarbonate solution (in mM): 120.2 NaCl, 25.1 NaHCO3, 4.7 KCl, 1.2
KH2PO4, 1.2 MgSO4, 1.3 CaCl2, and 5 D-glucose (Gissel and Clausen 1999).
Experiments were performed at room temperature to increase the physiological
stability of the tissues for the duration of the experiment (Segal and Faulkner 1985;
Gissel and Clausen 1999).

The bath was continuously bubbled with O2/CO2

(95%/5%) and maintained a working pH of 7.4. Suture (4-0 silk) was tied to tendons
at each end of the tissues, mounted between a fixed glass hook and a force transducer,
and placed in the bath. The FDS however had no proximal tendon and attached
directly to the distal end of the femur. Due to this anatomical design, the distal end of
the femur was cut and the attachment was left intact. Suture was then tied to the
distal tendon and the distal head of the femur to suspend the FDS.
experiments were performed with contralateral tissues as controls.
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All bath

Blockade of acetylcholine receptors
Acetylcholine (ACh) (A-2661, Sigma) was delivered to the bath at a
concentration of 88.1μM.

This concentration was determined to be more than

adequate to obtain maximal force production for the tissues. Baths were rinsed with
fresh Ringers solution between applications and incubated for 30 minutes with αbungarotoxin (00010, Biotium) at a concentration of 0.25 mM for EDL and 0.38mM
for SOL. Tissues were washed with fresh ringers for 30 minutes to remove any
unbound toxin. ACh was then applied at double the original concentration and
elicited no response (Harborne et al. 1978).

Stimulation Protocol
Muscles were removed and attached to a fixed glass hook using 4-0 silk
suture in tissue baths. The bodies of the muscles were suspended between two zigzag
electrodes(160152-12, ADI Instruments) and the proximal tendons were tied to a
force transducer (FT03D, Grass) to determine contractile force. Tissues were field
stimulated (S88, Grass) to determine optimum length.

Contractile force was

measured and recorded on a pen recorder (7D Polygraph, Grass). After optimum
length of the tissues were determined, tissues were electrically stimulated at 0.1Hz
(1.0-ms pulses) for 4 hours with supramaximal voltage (Gissel and Clausen 1999).

Stretch Protocol
For these experiments, resting length was measured in situ and tissues were
placed in baths with the distal ends attached to a glass hook, while the proximal ends
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were attached to a fabricated cam. The motor (Globe Motors, 409A582) was fixed
above the tissue bath and the cam was offset by 3 mm from the center of the motor’s
shaft. This design allowed for tissues to be stretched ±3 mm from resting length per
revolution which resulted in a ±14% and 15% stretch for the SOL and EDL
respectively.

This is within the physiological range of stretch (10-15%) as

determined for skeletal muscle (Chen and Grinnell 1997). Tissues were stretched at a
rate of 2 revolutions in 0.5 second at 0.1 Hz for an overall duration of 4 hours. This
protocol mimicked the contractile activity of the stimulation protocol used above.

Carbamylcholine Protocol
Muscles were removed and optimum length was determined as previously
described (see stimulation protocol).

After optimum length was established,

carbachol was added to the bath so that the final concentration was 10μM. Tissues
were exposed for four hours and contralateral control tissues were left in normal
Ringer’s solution for the duration of the experiment.

Tissue Processing
At the conclusion of the bath experiments, tissues were removed and frozen
on dry ice. To determine GDNF protein content, samples were subsequently dipped
in liquid nitrogen and smashed into a fine powder. Sample processing buffer (0.4 M
NaCl, 2 mM EDTA, 0.1 mM benzethonium chloride, 2 mM benzamidine, 20 KIU/ml
aprotinin, 0.5% BSA, 0.05% Tween-20 in PBS) was added and the mixture was
homogenized on ice. Samples were centrifuged at 13,000 x g for 30 min at 4ºC and
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supernatant collected and stored at -80ºC. GDNF protein content of the supernatant
was determined using enzyme-linked immunosorbant assay (ELISA).
Enzyme-linked immunosorbant assay. Enzyme-linked immunosorbant assays were
performed using capture antibody (R&D Systems, MAB212) and detection antibody
(R&D Systems, BAF212) to manufacturer’s specifications (R&D Systems). The
tetramethylbenzidine color reagent (Sigma, T-3405) was prepared according to
manufacturer specifications. The reaction was stopped with 0.1 M phosphoric acid
and absorbance measured at 450 nm.

Data Analysis and Statistics
For all bath studies, direct comparisons were made between the experimental
group mean and the unmanipulated, contralateral control group mean. GDNF ELISA
protein values of the experimental group were normalized to the control group values
and reported and a percent change from control ± the normalized standard error of the
mean.

In order to determine significance a t-test was performed, except when

variance was not homogeneous; in those instances Wilcoxon rank-sum comparisons
were used.

Significance was established at p ≤ 0.05 for all comparisons.
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Results

Field Stimulation
In order to determine the effects of field stimulation on skeletal muscle GDNF
content, EDL, FDS, and SOL were placed in isolated tissue baths and electrically
stimulated. After 4 hours of field stimulation tissues were removed and processed for
analysis of GDNF protein content. In the EDL, GDNF protein content significantly
decreased (44% ±18%) as compared to unstimulated, contralateral controls. The field
stimulated FDS significantly decreased compared to control (77% ±7%) while SOL
muscles had a significant increase (138% ±7%) when compared to control values
(Figure 25).
When tissues were pre-treated with α-bungarotoxin as previously described
and subsequently underwent field stimulation, both responses, the significant
decrease in the EDL and the significant increase in the SOL, were attenuated (125%
±31% and 140% ±16% respectively). In the FDS, α-bungarotoxin pre-treatment and
subsequent field stimulation caused a significant decrease (51% ±15%) compared to
unstimulated α-bungarotoxin treated control tissues (Figure 26). Treatment with α –
bungarotoxin alone had no significant effect on GDNF expression in EDL , FDS, or
SOL muscles (105% ±9%, 110% ±8%, and 74% ±16% respectively [Figure 27]).
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Effects of field stimulation on GDNF protein content of hindlimb
skeletal muscles.
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Figure 25. Effects of field stimulation on GDNF protein content of hindlimb skeletal
muscles. Four week old male Sprague-Dawley rats were euthanized and the extensor
digitorum longus (EDL), flexor digitorum superficialis (FDS), and soleus (SOL)
muscles were removed. Samples were placed into a tissue bath containing Ringer’s
solution and the contralateral tissues were used as unmanipulated controls. Four
hours of field stimulation caused a significant decrease in GDNF protein content of
the EDL (44% ±19%, n = 7) as compared to unstimulated control. Field stimulation
also caused a significant decrease in the FDS (77% ±7%, n = 6) In the SOL field
stimulation caused a significant increase (138% ±7%, n = 6) (*p ≤0.05).
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Effects of field stimulation on GDNF protein content of hind
limb skeletal muscles after treatment with α-bungarotoxin
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Figure 26. Effects of field stimulation on GDNF protein content of hind limb skeletal
muscles after treatment with α-bungarotoxin. Four week old male Sprague-Dawley
rats were euthanized and the extensor digitorum longus (EDL), flexor digitorum
superficialis (FDS), and soleus (SOL) muscles were removed. Samples were placed
into a tissue bath containing Ringer’s solution and the contralateral tissues were used
as unmanipulated controls. Four hours of field stimulation after a 30 minute pretreatment of the tissues with α-bungarotoxin had no significant effect on GDNF
protein content of the EDL (125% ± 31%, n = 9) as compared to unstimulated, αbungarotoxin treated controls. Field stimulation caused a significant decrease in the
FDS (51% ± 15%, n = 9) In the SOL field stimulation had no significant effect on
GDNF protein content compared to control (140% ±16%, n = 6) (*p ≤0.05).
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Effects of a-bungarotoxin on GDNF protein content of hindlimb
skeletal muscles.
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Figure 27. Effects of α-bungarotoxin on GDNF protein content of hindlimb skeletal
muscles. Four week old male Sprague-Dawley rats were euthanized and the extensor
digitorum longus (EDL), flexor digitorum superficialis (FDS), and soleus (SOL)
muscles were removed. Samples were placed into a tissue bath containing Ringer’s
solution and the contralateral tissues were used as unmanipulated controls. Tissues
treated with α-bungarotoxin for 30 minutes and then held at optimum length for 4
hours had no significant change in GDNF protein content in the EDL, FDS, or SOL
(105% ±9%,110% ±8%, and 74% ±16%; n = 6 for all) as compared to untreated
controls that were held at optimum length.
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Stretch
In order to determine the effects of passive stretching on GDNF content of
skeletal muscle, EDL, FDS, and SOL muscles were removed, and placed in isolated
tissue baths. Tissues were cyclically stretched every 15 seconds for 4 hours. Tissues
were removed and processed to measure GDNF protein content. The EDL had a
significant decrease in GDNF protein content (66% ±10%) as compared to control in
response to passive stretch. There was no significant effect on FDS or SOL muscle
GDNF protein content (95% ±8% and 108% ±10% respectively) after 4 hours of
stretching (Figure 28).
To determine the role of the nAChRs in this response, tissues were pretreated
with α-bungarotoxin to block nAChR activity. After treatment with α-bungarotoxin
and subsequent washes, muscles were cyclically stretched for 4 hours and GDNF
protein content was analyzed. There was no significant difference between the αbungarotoxin treated, passively-stretched EDL or FDS (85% ±13% and 86% ±14%)
and α-bungarotoxin treated, unstretched control tissues (Figure 29). For the SOL,
pretreatment with α-bungarotoxin and subsequent passive stretching caused a
significant increase in GDNF protein content (240% ±10%) compared to the αbungarotoxin treated, unstretched control (Figure 29).
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Effects of stretch on GDNF protein content of hindlimb skeletal
muscles.
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Figure 28. Effects of stretch on GDNF protein content of hindlimb skeletal muscles.
Four week old male Sprague-Dawley rats were euthanized and the extensor digitorum
longus (EDL), flexor digitorum superficialis (FDS), and soleus (SOL) muscles were
removed. Samples were placed into a tissue bath containing Ringer’s solution and
the contralateral tissues were used as unmanipulated controls. Four hours of cyclical,
passive stretching caused a significant decrease in GDNF protein content of the EDL
(66% ±10%, n = 6) as compared to unstimulated control. There was no significant
effect of passive stretching on GDNF protein content of the FDS (95% ±8%, n = 6) or
the SOL (108% ±10%, n = 6) as compared to the unstretched, contralateral control
tissues (*p ≤0.05).
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Effects of stretch with a-bungarotoxin on GDNF protein content
of hindlimb skeletal muscles.
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Figure 29. Effects of stretch with α-bungarotoxin on GDNF protein content of
hindlimb skeletal muscles. Four week old male Sprague-Dawley rats were
euthanized and the extensor digitorum longus (EDL), flexor digitorum superficialis
(FDS), and soleus (SOL) muscles were removed. Samples were placed into a tissue
bath containing Ringer’s solution and the contralateral tissues were used as
unmanipulated controls. There was no significant effect of 4 hours of cyclical
passive stretching after 30 minutes of α-bungarotoxin treatment on GDNF protein
content of the EDL (80% ±9%, n = 6) or the FDS (86% ±14%, n = 5) as compared to
the unstretched, α-bungarotoxin treated control tissues. Passive stretching after αbungarotoxin treatment caused a significant increase in GDNF protein content of the
SOL (240% ±10%, n = 6) as compared to unstretched, α-bungarotoxin treated
controls (*p ≤0.05).

97

Carbachol Treatment
To further characterize the role of the nAChRs in response to stimuli tissues
were exposed to 10μM of the nAChR agonist carbachol for 4 hours in the muscle
bath. After treatment with carbachol, EDL and SOL muscle GDNF protein content
was measured using an ELISA. There was a significant decrease in GDNF protein
content for the EDL (49% ± 28%) as compared to control. There was no significant
effect of carbachol treatment on SOL GDNF protein content (126% ±22% [Figure
30]).
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Effects of carbachol on GDNF protein content of hindlimb
skeletal muscles.
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Figure 30. Effects of carbachol on GDNF protein content of hindlimb skeletal
muscles. Four week old male Sprague-Dawley rats were euthanized and the extensor
digitorum longus (EDL) and soleus (SOL) muscles were removed. Samples were
placed into a tissue bath containing Ringer’s solution and the contralateral tissues
were used as unmanipulated controls. Four hours of treatment with 10uM carbachol
caused a significant decrease in GDNF protein content of the EDL (49% ±29%, n =
7) as compared to untreated control. Carbachol treatment had no significant effect on
GDNF protein content in the SOL (126% ±15%, n = 6) (*p ≤0.05).
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Discussion

Field Stimulation
The findings of this study demonstrate that GDNF protein content is
differentially regulated in skeletal muscle. Stimulation caused a significant decrease
in the EDL (44% ±19%, n = 7), while in the SOL (138% ±7%, n = 6) a significant
increase in GDNF protein content was observed. These findings are interesting
because the response to field stimulation seems to be both statistically significant in
magnitude and physiologically opposite in direction. This suggests that both the EDL
and the SOL respond to these conditions in a unique way and that inherent
differences in these tissue types may be responsible for the physiologically opposing
changes of GDNF protein content. One difference between these two tissue types is
the composition of the muscle fibers.
The EDL is composed primarily of fast-twitch muscle fibers with published
reports of 98% of the overall composition being of the fast-twitch phenotype
(Alnaqeeb and Goldspink 1987). The SOL on the other hand is composed primarily
of slow-twitch muscle fibers which account for approximately 89% of the overall
muscle fiber composition (Alnaqeeb and Goldspink 1987).

Nagano and Suzuki

(2003) demonstrated a developmental difference in GDNF protein content between
muscles of opposing fiber type composition (SOL [slow] and gastrocnemius [fast])
and suggested that inherent differences in muscle fiber composition might be a cause
in the GDNF protein content differences observed during development. Our data also
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lends support to this idea of differential GDNF protein expression between muscles
of different fiber-type composition. The observation of both the field stimulated EDL
and SOL to significantly change from control unstimulated tissues and change in
opposing directions suggests that they respond differently to electrical activity
initiated via field stimulation. Further support for a relationship to muscle fiber-type
composition is exemplified in the response of the FDS to field stimulation.
In the FDS, field stimulation caused a significant decrease (77% ±7%, n = 6)
but not to the same magnitude as observed in the EDL (44% ±19%, n = 7). Ariano et.
al. (1973) determined the FDS is composed primarily of fast-twitch muscle fibers, but
does contain more slow-twitch muscle fibers than the EDL. They determined the
slow-twitch muscle fiber content for FDS to be approximately 8%. Our laboratory
observations using immunohistochemistry also support these findings (Figure 10).
The results from field stimulation of the FDS demonstrate a response in between that
of the SOL and EDL in regards to GDNF protein content for a muscle with a slowtwitch muscle fiber-type composition that is also in between the SOL and EDL. One
issue with the results from the FDS experiment, however, is that these tissues were
not removed in the same manner as the EDL and SOL and some tissue damage and/or
factors involved in removal of the distal femur head may have an effect on the
response in this tissue.

Further investigation addressing the inherent differences in

tissue composition and physiology and their direct impact on GDNF protein
expression is warranted.
Another interesting result from this study was identifying the role that the
nicotinic acetylcholine receptors (nAChRs) have in the previously mentioned
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response to field stimulation. Field stimulation would allow for depolarization of all
membranes within the electrical field, thereby causing depolarization of the intact
synaptic terminal and subsequent release of neurotransmitter, ACh. Acetylcholine
binds to receptors at the skeletal muscle endplate and normally causes a small change
in end plate potential that can eventually lead to muscle membrane depolarization and
muscle contraction. In the field stimulation experiment, the muscle membrane is
directly depolarized and undergoes muscle contraction, but ACh is also released from
the terminals, binds to receptors and may activate other chemical messaging
pathways in the tissue. By adding the nAChR antagonist α-bungarotoxin we are able
to block the effects of these receptors and still allow for muscle membrane
depolarization and the subsequent events that result in skeletal muscle contraction.
We found that the significant decrease of GDNF content in the EDL caused
by field stimulation (44% ±19%, n = 7) was attenuated when the tissues were pretreated with α-bungarotoxin (125% ±31%, n = 9). However, in the SOL, field
stimulation with or without α-bungarotoxin pre-treatment appeared to cause an
increase in GDNF protein content.

While the GDNF protein content of the α-

bungarotoxin pre-treated group was not statistically different from control (140%
±16%, n = 6) the discrepancy appears to be due to be a result of an increase in the
variability of the data set and may not necessarily be a direct result of a change in
physiological response to stimulation.

However, in the absence of a direct

comparison between the stimulated SOL and the stimulated, α-bungarotoxin-treated
SOL, a definitive conclusion could not be made.
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These findings suggest that a change in GDNF protein content in the EDL
may be a result of nAChR activation and not a direct result of membrane
depolarization or subsequent muscle contraction.

The change in GDNF protein

content may instead be a result of nAChR activation. For the SOL, the physiological
response to stimulation appears to be only slightly affected if at all, by nAChR
activity. Instead, these tissues may regulate GDNF protein content in a manner that is
different from EDL, possibly as a result of mechanical stimuli, membrane
depolarization, changes in intracellular calcium levels, a result of muscle contraction,
or a number of other physiological processes that are not a direct result of nAChR
activity. While the reason for the change in GDNF protein content in these tissues
has not been determined, what has been identified in this study is that these two tissue
types differ in physiological response to electrical field stimulation and that these
responses also differ in regards to the role of the nAChRs in this response.
Field stimulation after pretreatment with α-bungarotoxin caused a significant
decrease in GDNF protein content of the FDS (51% ±15%, n = 9) as compared to the
unstimulated, α-bungarotoxin treated control group. This result might suggest that
GDNF protein content in this tissue is not affected by blockade of the nAChRs. This
response is similar to that of the SOL with respect to the role of the nAChRs but
similar to the EDL with respect to direction of change of GDNF protein content. The
FDS appears to again respond with characteristics similar to both the EDL and the
SOL. However, the result in the FDS might be affected by the methods of the tissue
dissection (i.e. presence of bone from distal femur) and should not be considered a
conclusive determination of the physiological response of normal tissue.
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Stretch
The effects of passive stretching on GDNF protein content of hind limb
skeletal muscles is similar to the effects observed with field stimulation. Like field
stimulation, passive stretching caused a significant decrease in GDNF protein content
of EDL (66% ±10%, n = 6) compared to unstretched controls. This response also
appears to be dependent upon nAChR activation. Pre-treatment of EDL with αbungarotoxin has no significant change (80% ±9%, n = 6) from control, but
attenuates the response to stretch. Chen and Grinnell (1997) have demonstrated that
there is a direct, mechanical modulation of the release of transmitter with stretch.
These results suggest that the effects of passive stretching of the EDL on GDNF
protein content are due primarily to an increase in transmitter release with stretch and
subsequent nAChR activation.

Blockade of the nAChRs with α-bungarotoxin

attenuated the effects of passive stretch on GDNF protein content in the EDL, much
as it did with electrical field stimulation.
The response of the SOL to passive stretching was once again different than
that of the EDL. Passive stretching had no significant effect on GDNF protein levels
as compared to unstretched controls.

Passive stretching after α-bungarotoxin

treatment caused a significant increase in GDNF protein content (240% ±10%, n = 6)
when compared to unstretched, α-bungarotoxin treated controls. This was the largest
change in GDNF protein content observed with any of the manipulations tested.

In

this tissue, mechanical activity mediated through passive stretch might act as a strong
signal to increase GDNF protein content.

This increase might be reduced by

neurotransmitter activity. This would explain why the increase in GDNF protein
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content is greatest when nAChRs are blocked via α-bungarotoxin and mechanical
activity is initiated with passive stretching. When passive stretching is performed
without α-bungarotoxin pre-treatment, mechanical release of neurotransmitter is
increased and this increased neurotransmitter activity may be responsible for partially
attenuating the effects of passive stretch in the SOL.
In the FDS the response with stretch once again shared similar results with
both the EDL and the SOL. Like the SOL, GDNF protein levels were unaffected by
stretch alone.

However, similar to EDL, when FDS were pretreated with α-

bungarotoxin and subsequently stretched there was no significant change from αbungarotoxin control FDS. This blended response to stretch stimulus further supports
the possibility of a skeletal muscle fiber-type specific response to activity, however
direct evidence linking specific fiber types to differences in regulation of GDNF
protein expression is still needed. These observations only lend support to this
hypothesis but do not directly test this phenomenon as whole muscle extracts were
used for GDNF determination and did not specifically assay skeletal muscle fibertype subpopulations.

Carbachol
To further investigate the role of the nAChR in GDNF protein expression we
used an agonist for these receptors, carbamylcholine or carbachol. We found that
similar to both field stimulation and passive stretching, treatment of these tissues with
10 μM carbachol caused a significant decrease in the EDL GDNF protein content.
These tissues lacked the coordinated mechanical activity associated with whole
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muscle contraction via field stimulation and the mechanical activity associated with
cyclical passive stretching and yet still had significant decreases in GDNF protein
content associated with both of these manipulations.

Even though the bath

application of carbachol is not as coordinated as NMJ delivery of ACh, we cannot
rule out the possibility of membrane depolarization and the subsequent processes that
may lead to generation of muscle tension in these bath experiments. We did attempt
to measure tensile force after carbachol application and it was not detectable, even
when the sensitivity was adjusted well beyond that used to record tension from field
stimulation and ACh dosages.
In the SOL, carbachol treatment was only able to cause a slight increase in
GDNF protein content but this response was not statistically significant. These
experiments were performed based on standard experimental values of carbachol for
skeletal muscle; however, future investigations should include the use of tissue
specific concentrations found using dose-response evaluations.
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Summary
One common trend throughout all of these experiments is that each muscle
type responds in a manner that is correlative to its muscle fiber-type composition.
The primarily fast-twitch EDL would only significantly decrease in GDNF protein
content in response to bath manipulations. The primarily slow-twitch SOL would
only significantly increase in GDNF protein content in response to bath
manipulations.

However, these observations with skeletal muscle fiber-type

composition are only correlative and are not the only possible explanation for
differences observed between these skeletal muscles. Furthermore, GDNF values
were measured from whole muscle extracts and any number of cell types within the
muscle could be responsible solely for, or in conjunction with skeletal muscle cells,
to account for changes in the expression of GDNF protein content.
These results do suggest that GDNF protein content of skeletal muscle is
regulated via activity and that the nAChRs may play an important role in this
response. We have determined that changes in GDNF protein content of different
muscles are regulated differently and that it is not adequate to conclude a response to
a stimulus like exercise or activity based upon the response of one muscle type as a
representative of all skeletal muscle responses.
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CHAPTER VII
DISCUSSION AND CONCLUSIONS
Disclaimer and Disclosure
For all studies where GDNF protein content was measured skeletal muscle
extracts were prepared from whole muscle preparations. This includes all cell types
within the skeletal muscle at the time of extraction including but not limited to;
skeletal muscle cells both mature and satellite cells, neuronal fibers, glial cells,
smooth muscle cells of skeletal muscle vasculature, endothelia cells of skeletal
muscle vasculature, red blood cells, white blood cells, fibroblasts and any other cell
that happens to be within the skeletal muscle at the time of extraction.

While

references in this dissertation are made to changes in GDNF protein content of
skeletal muscle we do not imply this to solely mean mature skeletal muscle fibers.
When using whole tissue preparations it is important to keep in mind the composition
of the tissue examined and the possible sources for GDNF protein content.
Histology
One of the primary results from our histology studies was the localization of
GDNF protein expression to the neuromuscular junction (NMJ). Previously, there
were conflicting reports citing that GDNF was in the region of the NMJ in human
tissue (Suzuki et al. 1998) and another report that did not find GDNF at the NMJ of
rat skeletal muscle (Russell et al. 2000). We too were unable to label GDNF at rat
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NMJ using standard histological procedures and found that successful labeling was
the result of a few years of trial and error troubleshooting.
GDNF is not produced in large amounts in skeletal muscle and when the
protein is quantified using ELISA, values of GDNF protein ranged from 2 – 100
pg/mg of tissue. Adding additional difficulty was the fact that GDNF protein is a
releasable signaling molecule that is intended to be exported out of the skeletal
muscle cells. The best possibility for identifying positive GDNF signal from skeletal
muscle would therefore likely occur if GDNF protein expression was concentrated
into a focal region, either internally in storage vesicles or externally tagged to the
muscle surface. Knowledge about its function and its trophic support for motor
neurons subsequently led us to initially investigate the neuromuscular junction.
When successful labeling of GDNF at the NMJ was finally attained we
noticed that GDNF labeling appeared in a hazy region associated with the nAChRs
labeled by α-bungarotoxin. This hazy appearance may be on the skeletal muscle
surface as faint signal sometimes continues along the length of the muscle fiber away
from the NMJ and appears between muscle fibers. GDNF has the ability to bind to
heparin-sulfate proteoglycans (HSPGs) (Hamilton et al. 2001; Davies et al. 2003;
Rider 2003) and it is possible that they may be used to concentrate GDNF protein at
the region of the NMJ. HSPGs have been shown to be used as a means to localize the
expression of at least one other NMJ-associated, extracellular, signaling protein
called neuregulin (Loeb 2003). This might explain the hazy appearance of GDNF
immunopositive labeling at the NMJ.

Future studies could clarify this implied
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association by using commercially available antibodies to determine if GDNF
signaling is co-localized to HSPGs.
Another interesting finding was that not every NMJ in rat muscle stained
positive for GDNF. This was also in agreement with the previous functional and
histochemical studies involving GDNF. It had already been determined that GDNFdeficient and GFRα1-deficient mice lost approximately 22-35% of the motor neurons
(Moore et al. 1996; Sanchez et al. 1996; Cacalano et al. 1998; Oppenheim et al.
2000).

Furthermore analyses of GFRα1 mRNA and protein found that only

approximately 25% of spinal motor neurons contained GFR α1 (Bergman et al.
1999). Our observations visually support these findings. However, GDNF-positive
endplate counts were not attempted due to the thickness of the muscle preparations
used.
We attempted to only visually compare endplates in the same field of view
and in the same plane of depth in the tissue. If whole muscle counts were performed
one could not say with certainty that the absence of GDNF immunopositive labeling
would be due to a lack of GDNF protein or an inability of the antibody to diffuse into
the deeper regions of the muscle preparations. Assessment for GDNF positiveendplates may be possible if the skeletal muscle preparations were thinner and had
uniform thickness.
Another interesting finding was that GDNF immunopositive labeling was
identified at NMJs of slow-twitch muscle fibers. These results were preliminary in
nature and repeated preparations are needed to confirm this initial finding.
Additionally an association with slow-twitch muscle fibers does not mean that GDNF
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is exclusively expressed in these tissues or even that it is expressed at all slow-twitch
NMJs. More information is needed, including labeling of endplates from fast-twitch,
fast-intermediate, and fast-oxidative muscle fibers in order to draw further
conclusions about GDNF protein expression and skeletal muscle fiber-type.
One skeletal muscle fiber-type that displayed positive GDNF staining within
the muscle fibers was the intrafusal muscle fiber type. Labeling of GDNF protein in
human intrafusal muscle fibers was demonstrated by Suzuki et. al. (1998). It was
later shown that GDNF protein was associated with intrafusal muscle fibers of mice
during development (Whitehead et al. 2005). We provided similar evidence for
GDNF immunoreactivity in the intrafusal muscle fibers of rat skeletal muscle.
Functional studies from mice demonstrated that it was the motor neuron
innervation of these intrafusal muscle fibers that was responding to changes in GDNF
gene expression (Whitehead et al. 2005). They claimed that all of the motor neuron
loss associated with GDNF heterozygous knockout could be accounted for by the γmotor neurons that innervate intrafusal muscle fibers. However no direct label for
motor neuron subtypes currently exists that selectively identifies γ- versus α-motor
neurons. Additionally they also pointed out that a small portion of extrafusal muscle
fibers also expressed positive labeling of GDNF protein in their GDNF

+/lacz

mice.

While GDNF has been shown to be associated with intrafusal muscle fibers by our
results and previous studies, their findings and ours suggest that extrafusal muscle
fibers also contain GDNF and that expression in these fibers occurs at the NMJ.
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Aging
An interesting result when comparing the two aging studies was the
observation that GDNF protein content varied significantly when the extraction
methods were altered. While methods provided by the manufacturer did not provide
a specific protocol for skeletal muscle processing, other published reports used
between 1:10 and 1:20 dilutions of tissue weight to processing buffer volume for
extracting GDNF protein from skeletal muscle. The protocol in our lab called for a
1:4 dilution. This became problematic because certain samples would become gellike while others remained in a liquid phase.
The inconsistency of sample processing was then addressed and changes were
made to the second study to change the dilution factor to 1:14. The original intent of
the second study was to add the results from the new time points to the results
attained in the first study. However, in this process vast differences in GDNF protein
content made it not possible to directly compare the GDNF protein content values
between studies. These apparent differences in extracted GDNF protein changed our
current processing protocol to include a higher dilution of skeletal muscle.
This concern was also the reason why in the bath studies, comparisons were
not made between content values but rather changes from contralateral,
unmanipulated control tissues and expressed as a percent change from control. This
ensured that differences in processing of skeletal muscle samples between studies did
not directly affect our statistical analyses of GDNF protein content.
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Rather

significant differences in protein content should then be due to the muscle bath
treatment itself.
We suggest that GDNF protein extraction from skeletal muscle may vary
depending upon the amount of available buffer in relation to the skeletal muscle
mass. It is therefore important, when comparing absolute values of GDNF protein
content between studies that the dilution factor used should be the same.
Additionally there may be a concentration at which GDNF protein content is
optimally extracted from skeletal muscles. Future work should include a step-wise
dilution analysis to assess this possibility to determine an optimum dilution factor for
GDNF protein extraction from skeletal muscle.
While the age-related changes that occurred in skeletal muscle were
previously discussed in detail (see chapter 4), interesting comparisons could be made
between the different responses of each skeletal muscle with regards to the process of
aging. For all tissues GNDF protein content did not significantly change throughout
normal adulthood (5 months – 19 months of age). During this time frame, the NMJ is
stable and does not undergo significant changes in morphology. Likewise, GDNF
protein expression in skeletal muscles does not undergo significant changes. This is
the only phenomenon that appeared to occur similarly for all three of the skeletal
muscles examined.
Both in early development and in late life GDNF protein content significantly
changed for the SOL and the FDS. These tissues followed the same pattern of GDNF
protein expression; highest at 1 month, decreased at 10 months, and elevated at 23
months of age. While both of these tissues had significant changes in GDNF protein
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content with age, the EDL did not appear to be significantly altered at 1, 10, or 23
months of age. These differences in GDNF protein expression at various time points
may be attributed to inherent differences in skeletal muscle fiber-type composition.
At both the 1 month and the 23 month time points neurological changes may
be occurring. It has been demonstrated that refinement of the NMJ in rat continues
after birth up until 1 month of age at which time the physical properties of the NMJ
are established and remain proportionate throughout adulthood (Balice-Gordon and
Lichtman 1990). Likewise significant effects of sarcopenia occurs in the last quartile
of an organisms life-span (Rosenberg 1997) which would begin at approximately 21
months of age in the rat (Kanda and Hashizume 1998). During these times the GDNF
protein content of the primarily slow-twitch SOL muscle was significantly higher
than the GDNF content of the primarily fast-twitch EDL muscle.

In normal

adulthood, when there are no significant neurological changes occurring in skeletal
muscles, GDNF protein content of the SOL was not significantly different than the
EDL. Together these results may suggest that neurological changes associated with
development or aging may have a significant effect on the GDNF protein content of
slow-twitch muscle fibers but may not affect fast-twitch muscle fibers in the same
manner. Future aging studies should address specifically the neurological changes
that may occur at these time points and look for histological evidence of denervation
or sprouting that can occur with advanced aging.
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Voluntary Running
This study began as a confirmation of methods and in the end generated
interesting information about GDNF protein expression in skeletal muscle with
exercise. We began our voluntary running study to confirm previous findings that
exercise had the ability to alter GDNF protein content in adult rat skeletal muscle.
Previously we had used forced treadmill running and wanted to change methods to a
voluntary running apparatus to reduce the negative reinforcement associated with
forced treadmill running. We found that voluntary running did indeed significantly
alter GDNF protein content of the EDL.
The GDNF protein content of the EDL significantly decreased in response to
voluntary running. This response due to exercise is opposite the previous result
attained with forced treadmill running. With treadmill running GDNF protein content
of the SOL significantly increased (Wehrwein et al. 2002). The initial experimental
design included the use of the SOL as well as the EDL in the voluntary running study
so that direct comparisons of the results from each study could be made. However
technical error not identified until after completion of the study, resulted in the
subsequent removal of the FDS. Nonetheless interesting comparisons were made
between the EDL and the FDS.
The intent of comparing the results between the SOL and EDL was to identify
if there were tissue specific responses in GDNF protein content with exercise.
However comparisons drawn between the responses of the FDS and the EDL
demonstrated this effect. While the EDL had a significant decrease in GDNF protein
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content with exercise, the FDS had no significant change.

Combined with the

previous results that SOL had a significant increase with forced treadmill running this
may suggest that exercise-dependent changes in GDNF protein content is skeletal
muscle specific. This phenomenon was also observed in the skeletal muscle bath
studies which will be discussed later in this chapter.
Results from this study also helped to further characterize the change in
GDNF protein content of skeletal muscle in response to exercise. Prior to this study,
GDNF protein content of skeletal muscle was analyzed shortly after the last bout of
exercise (Wehrwein et al. 2002). In this study our exercise group was not euthanized
until one week after the last bout of voluntary running. GDNF protein content of the
EDL was still significantly decreased after three weeks of voluntary running and one
week of rest when compared to sedentary control animals. This suggests that skeletal
muscle changes in GDNF protein content are long-lived. This activity-based, longlived alteration of neurotrophic factor protein expression by skeletal muscles may
have implications on long-term potentiation and learning and memory.
The electrical activity of both neurons and skeletal muscle are measured in
milliseconds. The effects that three weeks of exercise had on neurotrophic factor
expression, however, lasted at least one week beyond the last exposure to voluntary
exercise. This suggests that activity-related skeletal muscle adaptations may have
occurred to alter the baseline expression of GDNF. Long-term (24hr) exposure to
GDNF at the NMJ enhances transmitter release and Ca2+ influx into nerve terminals
during evoked transmission in a frequenin-dependent manner (Wang et al. 2001).
This phenomenon, in principle, is similar to adaptations that may occur to support
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long-term potentiation and learning and memory. If tissues are able to respond to
neuronal stimuli and adapt their neurotrophic factor expression, then those neurons
will receive continued neurotrophic support beyond the cessation of neuronal
stimulation.

This prolonged neurotrophic activity may, in turn, affect

neurotransmission. Additionally, frequenin is expressed in neurons throughout the
brain (Paterlini et al. 2000) and null mutation of frequenin in C. elegans was shown
to affect learning and memory (Gomez et al. 2001). However, the NMJ is only one
type of synapse and occurs in the peripheral nervous system and therefore the
physiological adaptations that occur at the NMJ may not completely apply for
synapses of the central nervous system.
Further investigation into the time-course of GDNF expression in skeletal
muscle is warranted. Studies should address the following questions; when is GDNF
protein content first significantly altered, are changes in GDNF protein content
dependent on intensity of activity, do changes in GDNF protein content reach a
physiological plateau, and how long after cessation of exercise is GDNF protein
content significantly altered?. Our results and the results from these studies may have
implications on the enhanced effects of training and neuromuscular facilitation.
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Bath Studies
The experiments involving tissue bath studies were intended to determine the
physiological cues associated with exercise that may be important for altering GDNF
protein content of skeletal muscles. Results from these studies demonstrated that the
response of GDNF protein content to various stimuli again appeared to be tissue
specific. For the EDL, all changes in GDNF protein content were either significant
decreases in GDNF content or no change. Conversely, all responses for the SOL
were either significant increases in GDNF protein content or no change. These
observations suggest that GDNF protein content is not expressed in the same manner
for all skeletal muscles, and therefore a change in GDNF protein content from one
skeletal muscle type should not be generalized to apply for all skeletal muscles.
With these unidirectional responses of both the SOL and the EDL one may
make a comparison between a change in GDNF protein and skeletal muscle fibertype composition.

When comparing the responses of these tissues from field

stimulation, stretch and carbachol treatment the magnitude of the change in GDNF
protein content appeared to be greater in the EDL than in the SOL. The EDL, which
has 98% fast-twitch muscle fiber composition, has a more uniform fiber-type
composition than the SOL, which is only 88% slow-twitch. To truly compare the
results according to fiber-type, one might prefer a skeletal muscle with 100%
composition of a single fiber-type. However such a skeletal muscle does not exist in
the rat hind limb. Alternatively, new methods involving the isolation of skeletal
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muscle fibers and experiments on individual skeletal muscle fibers may prove to be
useful in correlating these responses to skeletal muscle fiber-type.
In the EDL, both of the significant decreases associated with field stimulation
and stretch were attenuated by pre-treatment of the tissues with α-bungarotoxin. In
these tissues it appeared as though activation of the nAChRs caused a significant
decrease in GDNF protein content of the EDL. This was not the case for the SOL. In
these tissues, significant changes in GDNF protein content from control were only
observed in response to field stimulation and stretch after pre-treatment with αbungarotoxin.

This may suggest that in these tissues GDNF protein content is

increased by mechanical activity.
Stretch alone had no significant effect on GDNF protein content of the SOL.
It has been demonstrated that repetitive cyclical stretch causes an increased release of
ACh from nerve terminals (Chen and Grinnell 1997). In this case the increase in
GDNF protein content from the mechanical activity of stretch may have been
overshadowed by a decrease in GDNF protein expression due to possible nAChR
activation associated with increased release of ACh during cyclical stretch. Field
stimulation of the SOL also caused nAChR activation (data not shown) but it is
possible that the amount of force and mechanical activity associated with
depolarizing field stimulation of skeletal muscle may be a strong enough mechanical
stimuli to overcome this hypothetical nAChR activity-dependent decline. Again
clarification of these results may be attained by performing these experiments on
isolated skeletal muscle fibers preparations.
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Conclusions
One underlying theme that became apparent as a result of these combined
studies is that GDNF protein content is not expressed in the same manner for all
skeletal muscles. Results from our investigations in histology, voluntary exercise,
aging, and bath studies all suggest that GDNF is expressed differentially in the SOL
as compared to the EDL and that skeletal muscle fiber-type composition might be an
important factor in GDNF protein regulation. Therefore, a significant change in
GDNF protein content from one skeletal muscle should not be generalized to apply
for all skeletal muscles. In the future, care should be taken to address these tissue
differences in regards to regulation of GDNF protein in skeletal muscle.
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